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INTRODUCTION 
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1.1 Malaria as a burden to mankind 
Amongst many parasitic diseases that threaten the health of 
mankind, malaria causes the most casualties (Harinasuta et al. 
1982). 
Four Plasmodium species are known to infect man: P. falciparum, 
P. malariae, P. vivax and P. ovale. Although all four can cause 
severe clinical symptoms, P. falciparum is the species responsible 
for almost all of the deaths in malaria (Bradley et al. 1987). It was 
reported that the threat of malaria remained unchanged through the 
last decades of our century (WHO 1986). Almost 3 billion people 
live in areas where malaria formes a threat to their health. Still 
an estimated 2 million people die as a result of malaria infection 
each year. 150-200 Million cases of P. falciparum malaria are 
reported annually (Daroff et al. 1967; Grau et al. 1987). These 
cases are found all over the world, but mainly in malaria-endemic 
areas between lattitude 62° North and 40° South. In these endemic 
areas the continuous presence of suitable malaria vectors and 
climatological circumstances provide optimal conditions for the 
development of the P. falciparum malaria parasite. Although in 
Western-Europe and North-America environmental circumstances 
are unfavourable for the survival of both the vector as well as this 
parasite, reports of cases of imported malaria increase since the 
late seventies. Such countries include The Netherlands (Delamarre 
et al. 1979, Wetsteyn et al. 1992), France (Gentiline et al. 1981, 
Leger et al. 1981, Raccurt et al. 1990), Belgium (Holvoet et al. 
1982), Great Britain (Whitfield et al. 1984, Conlon 1990, Pryce et 
al. 1993), Italy (Majori et al. 1990), the Federal Republic of 
Germany (Heim et al. 1988) and the United States of America 
(Froude et al. 1992, Freedman 1992). 
Factors that increase the number of malaria infections include: (1) 
growth of the population, (2) ecological changes in relation to 
increase in population and economic development, (3) development 
of insecticide resistance of the vector and (4) the increased use of 
antimalarials leading to drug resistance of the parasite. 
The parasite has developed resistance against chloroquine and 
other anti-malarials in several tropical countries of South-
America, Central Africa and South-East Asia (Phillips-Howard et 
al. 1988, Gardner et al. 1981, Cook 1988). In the south of Viet Nam 
resistance against chloroquine, 4-aminoquinolines and Fansidar® 
has been rapidly developing (Vu Thi Panh 1984, 1984a), and has 
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reached levels up to 80% of cases with malaria (Malaria 
Interregional Meeting for Asia and the Western Pacific region, New 
Delhi, February 3-7, 1992, T. Harinasuta, personal communication). 
Delay of effective treatment and resistance to chloroquine, the 
drug most widely used, may contribute to the development of 
pernicious infections. Resistance to the drugs used for treatment 
of malaria has contributed to an increased mortality (48%) among 
hospitalized children with acute P. fa/c/'parum-infection in Viet 
Nam, while 22% of the hospitalized adults with cerebral malaria 
die of this disease (Jerusalem et al. 1984). 
1.2 Clinical manifestations 
Infection with malaria parasites in non-immune people is usually 
accompanied by clinical symptoms. Although infection with all 
four Plasmodium species can lead to disease, particularly 
infection with P. falciparum parasites can cause severe clinical 
symptoms such as cerebral malaria, which may be further 
complicated by severe anemia, renal failure, liver dysfunction, 
pulmonary edema or ARDS, hypoglycemia, shock or acidemia (WHO 
1990). One or more of these complications can occur independently 
of cerebral malaria. 
The following symptoms and findings are indicative for cerebral 
malaria (WHO 1986, 1990): 
- unrousable coma 
- presence of asexual forms of P. falciparum in the blood 
circulation 
- exclusion of other causes of encephalopathy 
In adults the development of cerebral malaria usually starts 
several days after the onset of fever, but in children the 
development of the cerebral syndrome may take less than two days 
(Warrel 1983). A generalized convulsion followed by unconsious-
ness usually marks the start of cerebral malaria. 
1.3 Human Cerebral Malaria 
Cerebral malaria occurs in 0.5-10% of P. falciparum-'mf ected 
patients (Spitz 1946, Sturchler 1989, WHO 1990) and may carry a 
high mortality rate reaching up to 50% (Endshaw et al., 1990, 
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Looareesuwan et al. 1983, Phillips et al. 1985, Warrel et al. 1982, 
White et al. 1982). Most cases of deaths due to P. falciparum 
malaria infection have been reported to result from this 
complication (Bradley et al. 1987). 
1.3.1 Pathology 
According to the WHO (1986) an essential pathological finding in 
cerebral malaria is the sequestration of parasitized erythrocytes 
in cerebral capillaries and postcapillary venules. This 
sequestration often leads to vascular obstruction in small blood 
vessels and margination of parasitized erythrocytes along the 
vessel wall in venules (Bruce-Chwatt 1985). The major site of 
sequestration appears to be the brain and is considered to be the 
cause of coma (McPherson 1985). In a study by Oo et al. (1987) in 
Burmese patients, sequestration was reported in all cases. 
However, in studies by Polder et al. (1989 thesis) on Vietnamese 
patients sequestration was only found in 13.8% of patients with 
cerebral malaria. 
In studies by Polder (1989), Jerusalem (1984), Spitz (1946) and 
Maegraith (1948) perivascular edema and loss of the integrity of 
the vascular wall often leading to petechial hemorrhages was a 
prominent feature. In Viet Nam cerebral petecchial hemorrhages 
were observed in 72% of patients with cerebral malaria (Jerusalem 
et al. 1983). In some patients brain edema was the only patho-
logical alteration found in autopsy material (Jerusalem 1984). 
1.3.2 Risk factors 
People who come into contact with P. falciparum for the first time 
are at risk of developing cerebral malaria. This can occur when 
people who live in malaria free cities migrate to rural areas 
(where the parasite still persists) or when non-immune travellers 
(e.g. tourists) go to endemic areas. 
People living in areas of unstable malaria are also at risk of 
developing cerebral malaria during epidemics because of the lack 
of immunity. 
The highest risk of developing cerebral malaria in regions where 
P. falciparum malaria is hyper- or holoendemic is found in young 
children between the age of six months and five years. In those 
areas acquired immunity prevents cerebral malaria in adults and 
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older children (Bruce-Chwatt 1952, Gilles et al. 1967, Lucas étal. 
1969); however, this immunity will fade when contact with the 
parasite has stopped. People leaving those areas for more than a 
year have an increased risk of developing cerebral malaria when 
they return (Maegraith 1973). 
The nutritional status also affects the development of cerebral 
malaria. Well nourished children are at a higher risk of developing 
cerebral malaria compared to malnourished children (McGregor 
1982) who in turn are at increased risk after refeeding (Murray et 
al. 1978). 
1.3.3 Therapy 
Cerebral malaria patients should be considered a medical 
emergency and if possible be admitted to an intensive care unit. 
Immediate intravenous administration of rapidly effective anti-
malarial drugs should be started as specific therapy. If the 
sensitivity of the parasite to antimalarial drugs is unknown, 
quinine should be used. Quinine is still considered a life-saving 
drug in these circumstances (WHO 1990) although quinine 
resistance occurs (Brasseur et al. 1992; Giboda et al. 1988; 
Karbwang et al. 1991). 
Although dexamethasone has been used in cerebral malaria to 
reduce edema as well as for its anti-inflammatory effect, its use 
is no longer recommended. Dexamethasone treatment did not 
decrease mortality (Hoffman et al. 1988) and even prolonged 
unconsiousness in a study by Warrell et al. (1982). Other ancillary 
treatments that are no longer recommended comprise the use of 
non-steroidal anti-inflammatory drugs, anti cerebral edema 
agents, low molecular weight dextran, adrenaline, heparin, 
prostacyclin, oxpentiphylline, cyclosporin A and hyperimmune 
serum (WHO 1990). 
1.3.4 Pathogenesis of human cerebral malaria 
Several theories have been proposed to explain the pathophysiology 
of cerebral malaria (WHO 1990). 
The sludging hypothesis: 
The earliest hypothesis was based on pathology of fatal P. 
falciparum cases. Histopathological examinations revealed a high 
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number of infected cells in cerebral capillaries and venules. Mainly 
late trophozoite and schizont stages, forms rarely seen in the 
peripheral blood, were thought to stick together and obstruct the 
blood vessels. This would strongly impair cerebral blood flow, 
eventually leading to sludging of the vessels (Gaskell et al. 1920, 
Knisely er al. 1941). Locally released toxic parasitic products were 
thought to induce the ensuing pathological events. 
More recently intravascular agglutination of parasitized as well as 
unparasitized erythrocytes (rosette formation) has been observed 
(Carlson et al. 1990; Ho étal. 1991; Treutiger étal. 1992) which 
may also contribute to obstruction of the vasculature. 
The permeability hypothesis: 
In 1972 Maegraith and Fletcher proposed a new hypothesis based on 
animal studies and on observations made by Rigdon (1942). He 
suggested that a kinin-induced increase in the blood-brain barrier 
permeability led to an outward leaking of plasma, resulting in 
cerebral edema (kinins = evanescent vasoactive peptides induced 
by the malaria parasite). This led to the use of anti-edema drugs 
such as dexamethasone, and anti-inflammatory drugs. 
Because of the differences between animal models and human 
cerebral malaria, this hypothesis was rejected (WHO 1986). 
Furthermore, Warrell et al. (1986) concluded that the blood-brain 
barrier in cerebral malaria patients was essentially intact, 
whereas Areekul et al. (1984) found an increased capillary 
permeability in patients with cerebral malaria. 
The mechanical hypothesis: 
Another hypothesis was based on microcirculatory obstruction 
resulting in local hypoxia and substrate depletion (WHO 1986). The 
obstruction is supposed to be the result of: 1) a decreased 
deformability of parasitized erythrocytes making it more difficult 
to pass through the capillary bed (Miller et al., 1972). 2) the 
adherence of parasitized erythrocytes to the endothelial wall 
(cytoadherence) (WHO 1986). A reduced cerebral blood flow would 
lead to anaerobic glycolysis resulting in lactic acidosis. One 
argument against this hypothesis is the fact that P. v/Vax-infected 
erythrocytes that are enlarged, do not induce the same pathological 
changes as observed in P. falciparum cerebral malaria (WHO 1986, 
1990). 
Recently a number of cytoadherence molecules have been 
6 
described, such as CD36 (Panton et al. 1987) as well as 
thrombospondin (Lawler 1986) that are both involved in adherence 
of infected erythrocytes (Roberts et al. 1985, Barnwell et al. 1989, 
Galinsky et al. 1992). Berendt et al. (1989) described a third 
adhesion molecule (ICAM-1) that can be induced on endothelial 
cells and binds to parasitized erythrocytes. The relevance of these 
molecules in the in vivo binding of parasitized erythrocytes has 
not been established yet. 
A major argument against this hypothesis is that Warrell et al. 
(1988) found that in Thai cerebral malaria patients there is no 
evidence of reduced cerebral blood flow. However, patchy 
microcirculatory obstruction together with adjacent areas of 
increased perfusion may make it difficult to measure an increased 
vascular resistance (Jerusalem et al. 1984). No changes in cerebral 
blood flow parameters were found when patients regained 
consiousness but arterial and cerebral lactate production was 
higher in comatose patients indicating anaerobic cerebral 
glycolysis and cerebral hypoxia (Warrell et al. 1988). CSF-lactate 
concentrations were higher in patients with cerebral malaria 
compared to patients with complicated non-cerebral malaria, and 
this was inversely correlated with CSF-glucose concentrations 
(White et al. 1985). CSF-lactate concentrations were significantly 
higher in fatal cases, however they considerably overlapped with 
the values of non-fatal cases (White et al. 1985). 
In summary, obstruction of blood vessels resulting in local hypoxia 
may together with parasitic glycolysis (Jensen et al. 1983) lead to 
increased lactate production in cerebral vessels as well as in the 
CSF. 
The immunological hypothesis: 
In the pathogenesis of cerebral malaria in rodent models 
immunological reactions appear to play an important role (see 
1.4.3). In man, indications of the involvement of immunological 
reactions in the pathogenesis of cerebral malaria mainly come 
from several indirect observations. Adam et al. (1981) found 
circulating immune complexes and complement activation in blood 
of cerebral malaria patients and indicated that this may lead to 
the development of vascular pathology. Brasseur et al. (1983) 
described impaired cellular immunity in cerebral malaria patients. 
Furthermore, Murray et al. (1978) described that malnourished 
children having a diminished cell mediated immunity are less prone 
7 
to develop cerebral malaria. Additionally, the neuropathological 
lesions in human cerebral malaria have been interpreted as a 
hyperergic reaction of the CNS to plasmodial antigens (Toro et al. 
1978). 
An important observation was made by Scuderi et al. (1986) and 
later by Kern et al. (1989), Kwiatkowski et al. (1990), Grau et al. 
(1989b) and Shaffner et al. (1991), who found elevated serum 
levels of TNF in patients with cerebral malaria. Elevated TNF 
levels arising from immunopathological reactions are considered a 
major factor in the pathogenesis of murine cerebral malaria (Grau 
et al. 1987). This will be discussed in greater detail in the 
following. 
1.3.5 Cerebral malaria and cytokines 
Many types of infections stimulate host mononuclear cells to the 
release of a variety of polypeptides, which are called cytokines 
(Dinarello et al. 1987). Particularly one of these cytokines, TNF, is 
considered important in the development of murine cerebral 
malaria (Clark et al. 1987a,b, 1988a,b, 1990a,b, Grau et al. 1987, 
1989a,b, 1990, Curfs et al. 1990). 
A number of observations made in human malaria indicate a role 
for TNF in cerebral malaria. In human cerebral malaria TNF levels 
are found to be elevated compared to non-cerebral malaria patients 
(Scuderi et al. 1986, Kern et al. 1989). Monocytes from acute 
malaria patients in the Gambia secrete significantly more TNF 
compared to monocytes from convalescent individuals 
(Kwiatkowski et al. 1989). In Malawi and Zaire, serum-TNF 
concentrations of children infected with P. falciparum were 
positively correlated with disease severity and mortality (Grau et 
al. 1989b, Shaffner et al. 1991). Furthermore, many of the clinical 
symptoms found after TNF injection, i.e. fever, chills, rigors, 
headaches, anorexia (Blick et al. 1987, Warren et al. 1987) and 
hypoglycemia (Tracey et al. 1986, 1988, Kettelhut et al. 1987) 
resemble clinical symptoms observed in severe malaria patients. 
Hypoglycemia, an often found complication in severe malaria, was 
found to correlate with serum-TNF levels in malaria patients in 
Malawi (Grau et al. 1989b). 
A shock-like state that sometimes complicates severe malaria can 
be found after infusion of TNF in rats, in quantities equal to those 
found in vivo during endotoxic shock (Tracey et al. 1986). 
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According to Clark et al. (1988b), injection of TNF into mice 
causes dyserythropoiesis and erythrophagocytosis comparable to 
the effects of falciparum malaria on the bone marrow (Phillips et 
al. 1986). Additionally, sequestration of erythrocytes and 
leucocytes might be mediated by increased TNF levels since TNF 
increases the adhesive properties of endothelial cells and 
leucocytes (Grau et al. 1990). 
Against a role for TNF in cerebral malaria argues the observation 
that some patients with uncomplicated disease have comparatively 
high serum-TNF levels whereas patients being severely ill may 
display lower serum-TNF levels (Kwiatkowski et al. 1990, Grau et 
al. 1989b). Complicating factors are the short half-life of TNF and 
the lack of accurate information on the disease history of the 
patient and his treatment before admission, making it difficult to 
interprete the data of single blood samples. Thus, treatment of 
cerebral malaria patients results in a rapid decrease of serum-TNF 
levels, even before clinical recovery is observed or before fever 
and parasitemia have disappeared (WHO 1990). Furthermore, 
clinical studies in Gambian children (Kwiatkowski et al. 1993) 
show that treatment with murine monoclonal antibodies against 
human recombinant TNF does reduce fever but does not affect 
mortality. Additionally, Kern et al. (1992) found that the 
concentration of soluble TNF receptors correlate with parasitemia 
and disease severity in human malaria. This suggests that 
excessive release of TNF may be controlled by a subsequent 
shedding of TNF receptors that might bind and deactivate 
biological functional TNF. 
Apart from TNF, other cytokines might be involved in the 
pathogenesis of human cerebral malaria. In the pathogenesis of 
experimental cerebral malaria IL-1, IL-3, GM-CSF and IFN-γ 
definitely play a role (Grau et al. 1988, 1989a,c, 1990, Clark et al. 
1987b, Curfs et al. 1990). 
1.4 Experimental Cerebral Malaria 
1.4.1 Experimental murine models 
Several experimental murine models have been described in the 
literature. Wright et al. (1968, 1971), Rest et al. (1979, 1983), 
Kamiyama et al. (1986) and Bakker et al. (1992) showed that 
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Plasmodium berghei infections in hamsters and rats can lead to 
hemorrhages in the brains of these animals. Petecchial 
hemorrhages were also found in the brains of mice infected with 
P. berghei (Rest 1982; Finley et al. 1982, 1983; Polder et al. 
1983,1992; Grau et al. 1986; Curfs et al. 1989; Clark et al. 1990b). 
In the experiments described in this thesis P. berghei Kl 73 
infections were studied in BW.LP, СВА/Са, С57ВІ/Щ, C57BI/6J 
and C57BI/6J nu/nu mice. 
1.4.2 Characteristics of a Plasmodium berghei K173 infection in 
mice 
During the second week after a blood-induced infection with 
parasitized erythrocytes, part of the mice (the proportion depends 
on the mouse strain used, and the number of parasites in the 
infectious inoculum) become progressively inert with a ruffled fur, 
humped back and locomotor disturbances or spasms. These mice 
show a dramatic decrease of their body temperature to values 
below 30°C usually within a period of 24 hours and die shortly 
thereafter. Histopathological examination of the brains of these 
mice, either post mortem or after being sacrificed when their body 
temperature decreases rapidly, reveals a high frequency of 
perivascular edema, cerebral hemorrhages, and intravascular 
accumulations of mononuclear cells adhering to the endothelium. 
The topographic distribution of these pathological changes 
coincides with major cerebral arteries and veins (Polder et al. 
1983). 
Mice that survive this critical period exhibit only a limited and 
transient decrease of their body temperature and die in the third 
week after infection or later. These mice do not exhibit any 
cerebral pathology, and die with high parasitemia, anemia, 
cachexia and frequently secondary infections. 
Death during the second week of infection, a progressive decrease 
in body temperature and hemorrhages in the brain are strongly 
correlated; therefore development of a low body temperature and 
the day of death have been used as external markers for the 
development of cerebral lesions in the study reported in this 
thesis. In C57BI/6J mice, the majority of infected animals (85-
100%) develop cerebral malaria. It was for that reason that this 
strain of mice was used in most of the reported experiments 
described in this thesis. 
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1.4.3 Pathogenesis of murine experimental cerebral malaria 
Although several theories have been developed to explain the 
pathogenesis of human cerebral malaria, most people working on 
this subject believe that immunopathological reactions and their 
products play an important role in the development of cerebral 
hemorrhages. 
Evidence for the involvement of T-cells in the pathogenesis of 
murine cerebral malaria came from experiments by Wright et al. 
(1968, 1971) who showed that neonatal thymectomy and treatment 
of mice with anti-T-cell serum prevented the development of 
cerebral malaria in golden hamsters. Subsequently, Finley et al. 
(1982) described that T-cell deficient nude mice do not develop 
cerebral malaria. In 1986, Grau et al. found that elimination of 
L3T4
+
-cells in mice infected with P. berghei ANKA prevented 
development of cerebral pathology. In addition, transfer of ЦТ 4 + -
cells from infected mice to newly infected mice accelerated the 
development of cerebral malaria in the latter. 
Additional information came from ultrastructural studies (Rest 
1982, 1983, Polder et al. 1983, 1992) in which during murine 
cerebral malaria monocytes, lymphocytes and parasitized 
erythrocytes were found to interact with each other and with 
endothelial cells. Furthermore, among other peripheral blood 
leucocytes pigment-containing macrophages were repeatedly 
observed in the center of hemorrhagic areas (Rest 1983, Polder et 
al. 1983). Thus apart from T-cells, macrophages and/or 
macrophage products can also be implicated in the development of 
cerebral lesions. 
1.5 Outline of this thesis 
This study was conducted to analyse the pathogenesis of cerebral 
malaria and to try to identify prognostic factors in order to 
develop new strategies for prevention and therapy. For this purpose 
we investigated an experimental model in which mice infected 
with the murine malaria parasite Plasmodium berghei К 1 7 3 
develop cerebral lesions similar to those found in cerebral malaria 
patients (Clark and Tomlinson 1949, Chapter 2). 
Previous studies of the P. berghei K173-mouse model (Eling et al. 
1980) analysing the effect of immunosuppressive measures on 
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morbidity and mortality, showed that splenectomy and a timely 
treatment with dexamethasone prevented death early in the second 
week after infection. Re-investigation of these measures led to 
the observation that cerebral malaria was prevented in 
splenectomized and dexamethasone treated mice (Chapter 2). 
In 1987, Grau et al. reported that the cytokine Tumor Necrosis 
Factor-α (cachectin, TNF), a major product of macrophages, played 
an important role in the development of cerebral lesions in mice. 
Dinarello et al. (1986) described an effect of TNF on the 
thermoregulative center in the hypothalamus. This suggested that 
the drop of the body temperature of infected mice as well as the 
coinciding development of cerebral malaria might be related to the 
release of TNF by activated macrophages. Since Beutler et al. 
(1986) reported that dexamethasone inhibited TNF production by 
macrophages, the protective effect of dexamethasone might be 
explained by inhibition of TNF production by macrophages in 
addition to the well established suppressive effect on T-cell 
function. 
Based on these data the following hypothesis was developed (fig.1): 
in mice infected with the parasite, monocytes and T-cells are 
activated. T-cell reactions, particularly those in the spleen, 
activate monocytes that subsequently produce and release TNF. 
Interaction with and adherence of lymphocytes and monocytes to 
the endothelium resulting in the local release of their products 
leads to endothelial damage and hemorrhages. 
Parasite products are considered to be responsible for the trig­
gering of the adverse immunological reaction. This prompted the 
analysis of the presence of blocking antibodies in serum of immune 
mice. Indeed, a timely treatment of mice with serum from 
malaria-immune mice (early during infection) prevents the 
development of cerebral malaria, whereas treatment with immune-
serum does not necessarily suppress parasitemia under these 
conditions (Chapter 2). 
If antibodies present in the serum of malaria-immune mice can 
prevent the development of cerebral malaria, it might be possible 
to immunize mice in such a way that the development of cerebral 
malaria is prevented during a subsequent infection with malaria 
parasites. Chapter 3 describes several procedures that may lead 
to immunization against cerebral malaria. These procedures 
include: increasing the number of infected erythrocytes in the 
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infectious inoculum, a two day immunizing infection given before 
the challenge, injection of large amounts of killed parasitized 
erythrocytes, or immunization with products produced and 
secreted by parasitized erythrocytes during in vitro culture prior 
to the challenge infection. 
Since the cytokine TNF is considered to be involved in the 
pathogenesis of cerebral malaria (Grau et al. 1987, Clark 1990b) 
the role of TNF in P. berpfteZ-infected mice was investigated. 
Chapter 4 describes treatment of infected mice with human 
recombinant TNF as well as with bacterial lipopolysaccharide 
(LPS), a strong inducer of TNF production, inducing cerebral 
malaria-like symptoms. Apart from an increased production of TNF 
during infection, TNF sensitivity is enhanced during malaria 
infection in mice. On the other hand repeated injections of 
sublethal amounts of TNF can prevent the development of the 
cerebral syndrome, whereas repeated or continuous treatment with 
LPS only prevents development of cerebral hemorrhages. A timely 
treatment with dexamethasone prevents cerebral malaria which in 
addition to its effect on T-cell-mediated reactions may also be 
mediated by its inhibitory effect on TNF production. Injection of 
TNF into dexamethasone treated mice results in cerebral malaria­
like symptoms, indicating that enhanced TNF receptor expression 
might explain increased sensitivity to TNF during infection. 
The elimination of monocytes, an important source of TNF, by a 
timely treatment with liposomal dichloromethylene diphosphonate 
can prevent development of the cerebral syndrome if administered 
before or early after infection. 
Production of TNF as well as TNF-receptor expression is influenced 
by the cytokine Interferon-/ (IFN-γ) being produced by activated T-
cells (Aggarwal et al. 1985, Gifford et al. 1987). The absence of 
cerebral malaria in infected mice treated with anti-T-cell serum 
or dexamethasone might be due to a decrease in IFN-γ production in 
these mice. Chapter 5 describes that particularly continuous 
treatment of mice with IFN-γ prevents the development of cerebral 
malaria. Treatment with antibody to IFN-γ did not prevent the 
development of cerebral malaria. Additionally, treatment with 
IFN-γ inhibits development of parasitemia. 
Because of the considerable overlap in biological function of TNF 
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and lnterleukin-1 (IL-1) and since IL-1 has proven to protect mice 
against lethal bacterial and fungal infections (van der Meer 1988, 
van der Meer et al. 1988, Ozaki et al. 1987, Czuprìnsky et al. 1987, 
van 't Wout et al. 1988) we investigated the role of IL-1 in the 
development of murine cerebral malaria. Chapter 6 describes that 
in contrast to TNF, injection of IL-1 does not induce or enhance 
cerebral malaria-like symptoms in infected mice. Low doses of IL-
1 given early during infection protect mice against cerebral 
malaria. However, as described in Chapter 7, treatment of 
infected mice with IL-1 receptor antagonist also prevents the 
development of cerebral malaria indicating that endogenously 
produced IL-1 plays a role in the pathogenesis of cerebral malaria. 
Figure 1 
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SUMMARY 
The majority of male C57BI/Rij mice died infected with Plasmodium 
berghei early in the second week. Death was closely correlated to 
collapse of the thermoregulation of the body, with perivascular 
edema and petecchial hemorrhages in the brain. Mice that did not 
show a collapse of thermoregulation (temperature drop below 30°C) 
and survived for more than 2 weeks after infection did not show 
hemorrhages. Development of this syndrome (temperature below 30°C; 
early death; hemorrhages) during infection depended on the presence 
of the spleen and was prevented by irradiation of the spleen or a 
timely treatment with dexamethasone, anti-T-cell serum or immune 
serum. 
INTRODUCTION 
In experimental Plasmodium berghei models, development of 
hemorrhages in the brain was prevented by neonatal thymectomy 
(Wright 1968) or treatment with anti-T-cell serum (Wright et al. 
1971, Rest 1983). 
The involvement of Τ helper cells of the L3T4
+
 Ly2" phenotype in the 
development of cerebral malaria in mice was determined by Finley et 
al. (1982), and Grau et al. (1986). 
Previous results using the P. berghehmouse model showed that a 
timely administered dexamethasone treatment or splenectomy before 
or during infection could prevent death of mice, which normally 
occured early in the second week (Eling 1980, 1982). When it was 
found that infected mice developed cerebral lesions early in the 
second week of infection (Polder et al. 1983), the role of different 
immunosuppressive measures in the development of cerebral lesions 
was re-investigated. 
This paper describes the characteristics of cerebral lesions in 
C57BI/RÍJ mice infected with P. berghei and the role of a spleen-
dependent Τ cell reaction sensitive to dexamethasone treatment in 
its pathogenesis. Additionally, cerebral lesions could be prevented by 
treatment with immune serum, suggesting that immune mice have an 
antibody-dependent protection against this syndrome. 
MATERIALS AND METHODS 
Mice: male, approximately 6 week-old, inbred C57BI/Rij mice were 
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obtained from the central animal facility of the University of 
Nijmegen. They were kept under SPF conditions and received water 
and food ad libitum. 
Body temperature: body temperature was measured with a digital 
thermometer (Technoterm 1200) introduced into the rectum and read 
after 10 seconds. 
Parasite: Plasmodium berghei, strain K173, was maintained by weekly 
intraperitoneal sub-inoculation of 105 parasitized erythrocytes (PE) 
into normal mice from the same strain and sex. For experimental 
infection, mice received 105 PE intraperitoneal^. 
Splenectomy: Mice were placed under ether anesthesia and the spleens 
extirpated following a lateral incision and ligation of the splenic 
pedicles. After surgery, the body wall was sutured and the skin closed 
with wound clamps. 
Irradiation of the spleen: mice were anesthetized with chloral 
hydrate (50 mg/kg) and fixed in a supine position. The body was 
shielded with a 4 mm lead plate containing a 2x2 cm opening over the 
splenic area. Irradiation was performed with a Stabilipan (Siemens) 
X-ray unit equipped with a Thoreaus 11 filter. The machine was 
operated at 250 kV, 15 mA. The irradiation dose was 400 rad and was 
delivered with a dose rate of 140 min. 
Dexamethasone treatment: dexamethasone-sodium phosphate 
(Oradexon, Organon, The Netherlands) was added to the drinking water 
of the mice (5 mg/l drinking water). This route was effective (uptake 
during day and night) and avoided stress due to manipulation of the 
mice. Sterilized drinking water was used and the dexamethasone-
containing solutions were kept in dark bottles. Fresh solutions were 
prepared twice weekly. Daily intake was approximately 3 ml of 
drinking water per mouse. Dexamethasone-containing drinking water 
was given from the day of infection until the end of the experiment. 
Sera: rabbit-anti-mouse Τ cell serum (ATS) was prepared by the 
intravenous injection of 109 thymus cells into a New Zealand rabbit 
two times during a two-week interval. One week after the second 
inoculation, the rabbits were bled, the serum collected, inactivated 
from 30 min at 56°C and stored at -20°C. ATS was absorbed to mouse 
red blood cells (three times using one volume of packed cells in total) 
and 0.2 ml of ATS per mouse was injected intraperitoneal^. Immune 
serum was obtained from mice that were immunized by 
intraperitoneal injection of 10 7 PE followed by sulphadiazine 
treatment (30 mg/l drinking water) 2 days later for a period of 31 
days. Two days after termination of sulphadiazine treatment, the 
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mice were challenged with 10s PE (¡.p.). Mice that did not develop a 
patent infection were considered to be immune (Eling et al. 1977). 
Because C57BI/Rij cannot be immunized by the above procedure, 
immune serum of Swiss mice was used for the treatment of 
C57BI/Rij mice. In experiments with C57BI/6J or B1OLP mice, both 
isologous and allogenic immune serum was used yielding essentially 
the same results (results not shown). 
Histology: mice were killed by an overdose of ether. Brain tissue was 
fixed in Carnoy's fluid for 4 hours. Paraffin sections (5цт) were 
stained with PAS and hematoxylin, Weichert's hematoxylin and eosin, 
or Bodian's stain. 
RESULTS 
Plasmodium bergheiinfection in male C57BI/Rijmice 
The characteristics of P. berghei infections in mice have been 
described previously (Eling et al. 1977). Briefly, С57ВІ/Щ mice 
inoculated with 105 PE exhibited a prepatent period of 4 days. An 
exponentially increasing number of parasitized oxyphilic red blood 
cells, reaching a peak infection of approximately 25% infected cells 7 
days after infection, followed. Despite a decreasing parasitemia after 
peak infection, the majority of animals died around 9 to 12 days after 
infection. In mice surviving this period the parasite switched to the 
infection of polychromatophilic erythrocytes and parasitemia 
increased again. All mice died in the course of infection. 
In this study body temperature of mice during the course of infection 
was measured. A dramatic decrease in body temperature shortly 
before death was measured in mice dying in the second week of 
infection. The data obtained in a typical experiment are depicted in 
Figure 1. 
Small temporary temperature changes in the first week of infection 
(Fig. la) were followed by much more severe changes from peak 
infection onwards. Mice that survived the second week of infection 
showed a substantial but limited decrease in body temperature in this 
period (Fig. lb) until, in such mice, a further decrease was observed 
shortly before death approximately in the fourth week of infection. 
Mice with a body temperature of 28°C or lower did not recover. 
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Figure 1: Body temperature of P. bergrief-infected male C57BI/Rij mice dying either 
early in the second week of infection (a, n=5), or later (b, n=3) in comparison to 
uninfected controls (shaded area; mean ±_s.d.; n=10). 
Histopathology of the brain of infected mice 
A high frequency of progressive perivascular edema and development 
of petecchial hemorrhages in the stratum moleculare of the 
cerebellum from day 7 after infection onwards (Figure 2) was a 
prominent feature in all mice with rapidly decreasing body 
temperature. Other areas of the brain were also affected but later and 
with lower frequencies. 
An occasional pigment-containing monocyte or granulocyte was found 
in the center of hemorrhages. Vascular sludging by parasitized 
erythrocytes and/or leucocytes as described in other systems with 
cerebral malaria was not prominent. 
Hemorrhages were present in the brains of mice that showed a 
dramatic decrease of body temperature, below 30°C, before death in 
the second week of infection, while hemorrhages were not found in 
the brains of mice that died in the third week or later in an untreated 
infection. 
Since death in the second week of infection, a progressive decrease 
of the body temperature (below 30°C) and hemorrhages in the brain 
were strongly correlated, body temperature and the period of death 
after infection were used as indicators for the presence or absence of 
cerebral lesions. 
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Figure 2. 
Petecchial hemorrhage in the stratum moleculare of the cerebellum of a P. berghei-
infected C57BI/RÍJ mouse 9 days after infection. Original magnification x250. Stained 
with PAS and hematoxylin. 
The effect of immunosuppressive measures and treatment with 
immune serum on development of cerebral malaria 
Splenectomy or dexamethasone treatment largely prevented the 
dramatic drop of body temperature (Figure 3) in the second week of an 
untreated infection. 
Hemorrhages were not seen in histopathological analysis of the 
brains of splenectomized or dexamethasone-treated animals, killed in 
the second week of infection. 
In subsequent experiments, the time after infection at which 
splenectomy or irradiation of the spleen could prevent death from the 
cerebral syndrome was determined. 
The time of death after infection was used as a marker for the 
cerebral syndrome. The results of these experiments are summarized 
in Figure 4. Mice were splenectomized or irradiated before or during 
infection and time of death (survival time) after infection recorded. 
To show the effect of treatment before or during infection, the 
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survival period of each mouse after infection was depicted in relation 
to the day irradiation or splenectomy was performed. The results are 
summarized in Figure 4. Post-mortem analysis was carried out to 
verify presence or absence of cerebtral lesions. 
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Figure 3. 
Body temperature of P. berghei-infected male C57BI/Rij mice. Infected untreated 
controls (Δ) are compared to mice splenectomized 14 days before infection (X), or 
treated with 5 mg dexamethasone/l drinking water ( · ) from the day of infection onward 
(5 mice per group; mean ±s.d.). 
Splenectomy, even when performed shortly before expected death, 
prevented mortality from the cerebral syndrome. Irradiation was 
effective for up to 6 days; thereafter, the proportion of mice that 
could be saved decreased (Figure 4). 
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Figure 4. 
Effect of splenectomy or irradiation of the spleen on day of death of P. berghe/-infected 
male C57BI/Rij mice. Day of death after infection of splenectomized (o) or spleen-
irradiated mice ( · ) is depicted on the day of splenectomy or spleen irradiation. Data of 
untreated controls (n=l 5) are summarized (shaded area; mean survival time + s.d.). 
The effect of ATS was analyzed in the same way as that used in 
splenectomized or irradiated mice. Time of death was used as a 
marker. Histopathological analysis in separate experiments was 
carried out for verification of cerebral lesions. The results of these 
experiments are summarized in Figure 5. Time of death of the animals 
is indicated in the figure above the day at which treatment with ATS 
was given. Data of mice treated with normal rabbit serum are 
presented together with the data of untreated controls. Treatment 
with ATS was effective in the prevention of the cerebral syndrome 
but became progressively ineffective towards the expected time of 
established lesions. A portion of infected mice died earlier than 
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control mice when given ATS on day 8. 
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Figure 5. 
Effect of treatment with anti-T-cell serum (ATS) on day of death in P. bergVie/'-infected 
male C57BI/Rij mice. Day of death ( · ) after infection is depicted on day of treatment 
except for two groups which received ATS twice (results in the middle) and for untreated 
or serum-treated controls (summarized separately). 
Splenectomy, spleen-irradiation or ATS treament had variable effects 
on parasitemia. Parasitemia decreased slightly after splenectomy and 
increased after treatment with ATS, particularly when ATS was 
applied early after infection. At later periods during infection, 
immunosuppressive measures became less effective (results not 
shown). All measures prevent development of the cerebral syndrome. 
Therefore, accompanying changes in parasitemia are not related to 
development of hemorrhages. 
The effect of treatment with P. berghei-immune serum (IMS) was 
similarly investigated. Measurements of the parasitemia were taken 
on day 7 (average peak day of infection observed in controls). The 
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results are summarized in Figure 6. Except for the results of normal 
serum-treated and untreated controls, the average parasitemia is 
depicted on the day when serum treatment was given. 
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Figure 6. 
Effect of treatment with 0.2 ml of immune mouse serum (IMS) on day of death of P. 
berghei-tnfected male C57BI/Rij mice. Day of death ( · ) after infection is depicted on the 
day of treatment with anti-P. berghei immune serum, except for untreated or serum-
treated controls (depicted separately). Parasitemia of different IMS-treated groups 
observed 7 days after infection is depicted in the same way (o). 
Treatment with immune serum prevented development of the lethal 
cerebral lesions until day 7 after infection; thereafter treatment 
with immune serum failed progressively. Immune-serum treatment 
reduced parasitemia more when applied early during infection, i.e. day 
4, rather than during later periods after infection, i.e. day 7. Since 
parasitemias of animals treated with IMS on day 6 were comparable 
to the data of (serum) controls this indicates that the IMS effect on 
the cerebral syndrome was independent of parasitemia. Comparable 
results were obtained by treatment with IgG from immune serum 
(results not shown). Treatment with normal mouse serum, but not 
with its IgG fraction, prevented development of lethal cerebral 
lesions in a proportion of the mice. 
10 s PE 
• 
36 
The effect of immunosuppressive measures and immune-serum 
treatment on development of the cerebral syndrome has also been 
determined in infected B10LP and C57BI/6J mice. Under comparable 
conditions, the development of the cerebral syndrome was prevented 
and no difference was observed in animals given serum from 
syngeneic or allogeneic immune mice, although higher immune-serum 
levels were needed to obtain the same effect (unpublished results). 
DISCUSSION 
A remarkable decrease in body temperature preceding death early in 
the second week after a P. berghei infection was strongly correlated 
to development of hemorrhages in the brain. 
Pigment-containing macrophages were repeatedly observed in the 
centre of hemorrhagic areas. Electron microscopic investigations 
supported the observation of Rest (1983) that monocytes with or 
without digested parasites are located in and around cerebral vessels 
of P. òergAie/'-infected mice possessing the cerebral syndrome (Polder 
et al. 1983). These features closely resemble the appearance of the 
interaction of monocytes and macrophages with cardiac endothelium 
(Eling et al. 1984). Macrophages appear to play an important role in 
the development of the cerebral lesions. Macrophage products, such as 
tumor necrosis factor (TNF-a), may be important in the development 
of cerebral malaria as reported by Grau et al. (1987). Dinarello et al. 
(1986) described an effect of TNF on the thermoregulative centre of 
the hypothalamus. This might suggest that the observed drop in body 
temperature of infected mice is related to the release of TNF from 
activated macrophages; however, hemorrhages in that area may also 
produce the same effect (Polder et al. 1983). 
Immunosuppressive measures, i.e. splenectomy, irradiation of the 
spleen, treatment with dexamethasone or ATS prevented the severe 
drop in body temperature, the development of hemorrhages and death 
in the second week after infection. 
The effect of splenectomy and irradiation of the spleen on the 
cerebral syndrome suggests a role for a spleen-dependent reaction in 
its pathogenesis. 
Wright et al. (1971) and Rest (1983) reported that treatment with 
ATS or neonatal thymectomy prevented development of hemorrhages 
in P. berpne/'-infected animals. The results of Finley et al. (1982) 
working with both Τ cell deficient nude mice and the euthymic parent 
strain, also indicated the involvement of Τ cells in cerebral malaria. 
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Spleen-dependent Τ cell reactions have been associated with other 
pathological changes as well, e.g. liver pathology, thymus involution 
and loss of immune reactivity towards newly introduced antigens 
(Eling 1980, 1982), suggesting a common mechanism for pathological 
changes in different organs. 
Therefore, spleen-dependent Τ cell reactions are probably involved in 
the development of cerebral lesions. 
Dexamethasone treatment prevented the development of the cerebral 
syndrome. Previous observations in this parasite-mouse model 
showed that mortality in the second week of infection (indicative of 
the cerebral syndrome) could only be prevented effectively by 
dexamethasone treatment when applied before day 5 of infection 
(Eling 1982). Beutler et al. (1986) reported that dexamethasone 
inhibited TNF production in macrophages, though it was ineffective in 
the post-transcriptional phase when mRNA for TNF production nad 
already been formed. Since the importance of TNF has been indicated 
in the pathogenesis of cerebral malaria (Grau et al. 1987) 
dexamethasone, apart from its well-known effect on lymphocytes, 
may inhibit the production of TNF by macrophages during infection 
and prevent the development of the cerebral syndrome. At later 
periods during infection the macrophages have synthesized mRNA for 
TNF production and become insensitive to dexamethasone. 
The effectiveness of immune-serum (or IgG) treatment indicated that 
immune mice have developed an antibody-dependent immune reaction 
against the cerebral syndrome. This makes it likely that parasite-
derived antigen(s) or surface determinant(s) of infected cells 
triggers a spleen-dependent Τ cell reaction(s) that develops the 
syndrome. Therefore, antibodies raised against antigens derived from 
parasites or parasitized erythrocytes should not only be tested for 
their ability to prevent or inhibit parasite proliferation, but also for 
their ability to prevent development of immunopathological reactions. 
The partial effect observed by treatment with normal mouse serum 
needs further attention. 
In summary, the observations suggest that parasite antigens can 
trigger Τ cell reactions that are spleen-dependent. These reactions in 
turn may activate macrophages that then release TNF. These immuno­
pathological reactions may play an important role in the development 
of the cerebral syndrome of the P. berghei-mouse infection and can be 
stopped or their development prevented when the antigen(s) is 
inactivated by the corresponding antibody. 
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SUMMARY 
The development of cerebral lesions in Plasmodium berghei-
infected mice was dependent on the strain of mice and the size of 
the infectious inoculum. In particular, C57BI/6J mice develop 
cerebral lesions when infected with low numbers of parasitized 
erythrocytes. By increasing the number of parasites in the 
infectious inoculum, the percentage of animals that develop 
cerebral malaria is decreased. 
Varying degrees of protection against the development of cerebral 
malaria can be obtained by several methods of immunization: (1) 
Injection of mice with large numbers of disrupted parasitized 
erythrocytes one or two weeks before the challenge infection 
(protection up to 70%). (2) A two day immunizing infection given 9 
or 14 days before the challenge infection (protection up to 85%) or 
(3) Injection of mice with plasmodial exoantigen preparations one 
week before the challenge infection (variable protection-rate, up to 
100%). 
In all mice protected against cerebral malaria, parasitemia is not 
affected by the immunizing treatment indicating that protective 
mechanisms against cerebral malaria and parasitemia are 
independent. 
INTRODUCTION 
Primary Plasmodium berghei K173 and ANKA infections are usually 
lethal in mice. In several mouse strains, the parasite causes lethal 
cerebrovascular lesions associated with immunopathological 
reactions (Lambert & Grau, 1989, ANKA; Rest 1983, ANKA; Grau, 
Piguet, Enger et al., 1986, ANKA; Curfs, Schetters, Hermsen et al., 
1989, Kl 73). Development of this type of cerebral pathology 
depends on the presence of T-cells (Curfs et al. 1989, Kl 73), 
particularly CD4+-cells (Grau et al. 1986, ANKA), indicating the 
involvement of a T-cell dependent immunopathological reaction. 
Since timely treatment of infected mice with antibodies from 
malaria-immune mice could prevent the development of cerebral 
lesions in P. berghei K173, it was suggested that: (1) timely 
acquired antibody-dependent immunological reaction(s) might 
protect against cerebral pathology in mice (Curfs et al. 1989) and 
(2) the interaction of these antibodies with parasite antigen(s) 
might prevent stimulation of the immunopathological T-cell 
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reaction. 
This paper describes experiments using live or disintegrated P. 
berghei K173 parasitized erythrocytes (PE) or parasitic products in 
the development of protection against cerebral malaria. 
MATERIALS AND METHODS 
Mice: female C57BI/6J mice and male В7O.LP mice were obtained 
from colonies maintained at the Central Animal Facility of the 
University of Nijmegen. Male C57BI/Rij mice were obtained from 
TNO, Rijswijk, The Netherlands. All mice were housed under 
specific pathogen-free conditions in plastic cages and received 
water and standard RMH food (Hope Farms) ad libitum. A l l 
experimental mice were infected intraperitoneally with parasitized 
erythrocytes from blood of infected donor animals of the same 
strain and sex. 
Body temperature: body temperature was measured with a 
Technoterm 1200 digital thermometer (Thermotex, The Hague, The 
Netherlands) that was inserted in the rectum and read after 
stabilization of the read-out (18 seconds). 
Parasite: Plasmodium berghei, strain K173, was used in all 
experiments and was maintained by weekly transfer (i.p.) of 10 5 
parasitized erythrocytes (PE) in naive C57BI/6J mice. Untreated 
infections with this parasite in mice are always lethal. 
Parasitemia: thin blood films were made from the tail blood of 
infected mice, stained with May-Grunwald and Giemsa's solutions 
and used to determine the parasitemia. 
Cerebral malaria (CM): in our mouse model, the majority of mice 
infected with P. berghei strain K173 exhibit a dramatic decrease in 
body temperature about twenty-four hours before death, in the 
second week after infection. Histological analysis shows petecchial 
hemorrhages in the brains of all mice (Curfs et al. 1989). Infected 
mice that survive the critical period of the second week after 
infection experience a transient and limited decrease of their body 
temperature during this period and eventually die 3 weeks after 
infection or later, however, without histopathological changes in 
their brains (Curfs et al. 1989). There is a strong correlation 
between the progressive decrease of the body temperature, death in 
the second week after infection and the presence of hemorrhages in 
the brain. 
Chloroquine treatment: chloroquine (Nivaquine) was added to the 
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drinking water at a concentration of 100 mg base per liter for a 
period of five days either to prevent proliferation of injected 
parasites or to radically cure infected mice. The average water 
uptake per mouse per day was approximately 3 ml resulting in a 
chloroquine uptake of 0.3 mg base/mouse/day. 
Isolation of parasitized erythrocytes: isolation of PE from infected 
blood was carried out as described by Eling (1977). Infected mice 
were bled on day 7 or 8 after infection using LPS-free heparin as an 
anti-coagulant. The sample was diluted three times in RPMI-1640 
medium containing 5U of heparin per ml and was run over a column 
containing three volumes of Sephadex G-150 Superfine (Phamacia) 
and one volume SE-23 (Servaceli) to remove the leucocytes. The 
eluate was diluted to six times the original blood volume and 
layered onto a cushion of 72% Percoli (Pharmacia). After 
centrifugation (25 minutes; 2000 g), the layer of cells on the 
Percoli cushion containing the parasitized red blood cells was 
taken and washed three times with medium. The resulting cell 
suspension contained over 95% PE. 
Disruption of parasites: Percoll-purified PE at a concentration of 
108 or more per 0.2 ml suspended in PBS (phosphate buffered 
saline) were disrupted by repeated freezing and thawing. 
Preparation of exoantigen: parasite exoantigens were prepared by 
the method described by Bate, Taverne & Playfair (1988). Mice 
infected with 10s parasites were bled 7 days later. The infected 
blood was washed twice in sterile PBS and incubated for 24 hours 
at 37°C in an atmosphere of 5% C02 in air at a concentration of 108 
parasitized cells per ml PBS. After incubation, the sample was 
centrifuged (5 minutes; 1000 g), boiled (5 minutes), then 
centrifuged again (5 minutes, 3000 g), and dialysed against PBS. 
The supernatant was used to immunize mice. Control preparations 
were made from normal erythrocytes using the same procedure. 
Exoantigen preparations were used fresh and occasionally after 
storage at -20°C for a period of two weeks. 
Exoantigen ELISA: microtiter plates were coated with exoantigen 
preparations in phosphate-buffered saline (PBS). For each batch an 
optimal coating concentration was determined. Coating with 
exoantigen was carried out at 4°C overnight; the plates were 
emptied and subsequently treated with 0.5% Tween-20 in PBS. The 
plates were washed and incubated with serial dilutions of test 
serum for 1 hour at room temperature. Then they were washed 5 
times with PBS and incubated for 1 hour at ambient temperature 
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with Goat-anti-Mouse IgM-peroxidase according to manufacturers 
instructions (Southern Biotechnology Associates, Inc. USA). The 
reaction was stopped with 4N H2S04 and the result read in an 
ELISA-reader at 450 nm. Normal mouse serum and serum from a 
stock obtained from a pool of malaria-immune mice were used as 
negative and positive controls respectively. The titers are 
expressed as the percentage of the titer observed in the serum-
stock from malaria-immune mice. Antibody titers were determined 
7 or 9 days after the immunizing infection or 9 days after 
immunization. 
Methods of immunization: 
(1) immunization with disrupted parasitized erythrocytes: The 
equivalent of 10 8 disrupted PE was injected intraperitoneal^ as an 
immunizing dose. No adjuvants were used. Mice immunized with 
these suspensions were also treated with chloroquine to exclude 
the possibility that a parasite surviving the freezing and thawing 
procedure could proliferate. Groups of immunized mice were 
challenged either 7 or 14 days later with ΙΟ3 PE. parasitemia, body 
temperature and mortality were scored. Cerebral malaria was 
confirmed by histological analysis of brain tissue post-mortem. 
(2) immunizing infection: Individual groups of mice were infected 
with varied amounts of PE (103, 10s, 107 PE/mouse) and two days 
later the infection was cured by chloroquine treatment. When 
chloroquine treatment was started, none of the mice exhibited a 
patent parasitemia independent of the number of parasites in the 
infectious inoculum. Either 9 or 14 days after the immunizing 
infection, which was terminated by chloroquine treatment, mice 
were challenged with ΙΟ3 PE and their parasitemias, body 
temperatures and mortalities were recorded. In all cases post­
mortem histopathological analysis was performed to determine the 
presence of cerebral pathology. 
(3) immunization with exoantigens: Mice were immunized with 
exoantigen or control preparations 7 days before challenge with 103 
PE. Five independently prepared batches of exoantigens were tested. 
In addition, in one experiment, exoantigens were combined with 
Complete Freund's Adjuvants (1:1) and used for immunization 7 and 
14 days before the challenge infection with 103 PE. 
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RESULTS 
Cerebral malaria in several mouse strains 
Parasitemia, body temperature and mortality of three different 
mouse strains infected with ΙΟ3 PE are depicted in figure 1. 
During the exponential increase in parasitemia between days 6 and 
12 after infection, the parasites were found in oxyphilic 
erythrocytes. In mice surviving this critical period, reticulocytosis 
developed and reticulocytes were predominantly infected until the 
mice finally died. Depending on the strain, all, or the majority of 
the mice died in the second week after infection. 
Characteristically, a fraction of the C57BI/Rij mice (3 out of 11; 
27%) did not die early. 
Histopathological analysis of the brains of the mice that died in the 
second week after infection always exhibited petecchial 
haemorrhages and perivascular oedema as reported previously 
(Curfs et al. 1989; Curfs, van der Meer, Sauerwein et al. 1990). Mice 
that survived the critical period and died in the third week after 
infection or later did not exhibit the typical cerebral pathology. 
A dramatic decrease of the body temperature to critical levels of 
30°C or lower was closely associated with early death and 
development of cerebral hemorrhages. In mice surviving the critical 
period, a variable and transient decrease of the body temperature 
was found in the second week. Mice with cerebral lesions (oedema 
and petecchiae) always died in the second week of infection and 
always exhibited a progressive decrease of their body temperature 
to values below 30°C in all experiments reported in this paper. 
Days after infection 
5 7 9 11 13 
Daye after infection 
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Figure 1. 
Parasitemia, body temperature and mortality of mice of 3 different strains after 
infection with 103 parasitized erythrocytes. ( · ) Body temperature (average); (o) 
parasitemia (average); (-) mice with cerebral hemorrhages; (--) mice without 
cerebral hemorrhages. Mortality is indicated above the horizontal axis as the number 
of mice that died on that day. 
The effect of the infectious inoculum on cerebral malaria 
Groups of mice were infected with increasing numbers of parasites 
and parasitemias, body temperatures and mortality rates were 
recorded. The results of a typical experiment using either 1 0 3 o r 
Ί 0 7 parasites for infection in female C57BI/6J mice are depicted in 
figure 2. In addition, table 1 shows the effect of the inoculum size 
on the development of CM in different mouse strains. When mice 
were infected with increasing numbers of parasites, the proportion 
of mice developing cerebral malaria gradually decreased. On the 
other hand, a maximum number of mice developed the cerebral 
syndrome when 103 or fewer parasites were used for infection. 
Considerable variation of the effect of the inoculum size on 
development of CM was found in different parasite-mouse strain 
combinations (table 1). Both genetic factors as well as differences 
between mice of a given inbred strain may play a role in protection 
against CM. 
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Figure 2. 
Parasitemia, body temperature and mortality after infection of C57BI/6J mice with 
IO3 or 107 parasitized erythrocytes (PE). Only the body temperature of mice that 
developed cerebral malaria was included in the data of the mice infected with IO3 PE 
( · ) and only the body temperature of mice that did not develop cerebral malaria in the 
data of the mice infected with 107 PE (o). 
Mice that died during the second week after infection exhibited 
hemorrhages in their brains as revealed by post-mortem histo­
logical analysis. This was independent of the parasite dose used for 
infection. None of the mice that died after the second week 
exhibited the cerebral syndrome. Such mice experienced a transient, 
but significant decrease in their body temperature which stabilized 
until shortly before death. Again, this was independent of the 
parasite dose used for infection. With some variation between the 
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parasite-mouse strains used in these experiments, the higher the 
parasite load early after infection, the higher the chance of not 
developing the cerebral syndrome. A high parasite load early after 
infection may enhance a timely development of an antibody-
dependent protection against development of the cerebral syndrome. 
This possibility was suggested in experiments where mice were 
protected against CM when treated with immunoglobulins from 
malaria-immune mice before day 5 of infection (Curfs et al. 1989). 
The following experiments were done to analyse this further. 
Immunization against cerebral malaria with disrupted parasitized 
erythrocytes 
Six independent experiments were performed to test whether 
disrupted PE could be used for immunization against cerebral 
malaria in C57BI/6J mice. Protection against cerebral malaria was 
observed in only three out of these six experiments. The 
summarized data (not shown) of these three experiments revealed 
that 4 out of 8 mice and 7 out of 10 mice were protected when the 
challenge infection was given 7 or 14 days, respectively, after the 
immunizing dose, while no mice were protected in the untreated 
control groups (0 out of 11 mice). This immunization procedure had 
no effect on the course of the parasitemia during the challenge 
infection irrespective of protection against CM during the challenge 
infection. Similarly immunization with disrupted PE did not change 
the pattern of the body temperature or day of death after infection 
as observed in corresponding non-immunized infected controls 
whether protected against CM or not (results not shown). 
In the three unsuccesful experiments, immunization with disrupted 
PE did not protect at all, 0 out of 9 mice were protected in both the 
immunized and non-immunized control groups. This outcome was 
also independent of the day of challenge, i.e. whether the infection 
was given 7 or 14 days after immunization. 
Previous experiments showed that live parasites were more ef-
fective than parasite extracts in induction of protection against 
the parasite (Jerusalem & Eling, 1969), therefore, the effect of live 
parasites for induction of protection against CM was investigated 
here. 
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TABLE 1 
EFFECT OF INFECTIVE DOSE ON THE DEVELOPMENT OF 
CEREBRAL MALARIA IN DIFFERENT MOUSE STRAINS 
STRAIN 
C57BI/6J 
C57BI/RÜ 
B10.LP 
INFECTIVE 
DOSE 
ΊΟ
1
 PE 
102PE 
103FE 
105FE 
107PE 
103PE 
104PE 
105PE 
106FE 
107PE 
103FE 
104PE 
105PE 
106FE 
107PE 
MICE 
η 
7 
12 
99 
5 
33 
18 
15 
18 
3 
18 
17 
15 
13 
3 
18 
WITH CM * 
% 
100 
92 
92 
60 
9 
72 
86 
61 
67 
33 
82 
93 
85 
33 
50 
* CM=cerebral malaria 
The effect of an immunizing infection on cerebral malaria 
The results of four independent experiments using short-term PE 
infections (2 days) terminated by chloroquine treatment for the 
immunization against CM in C57BI/6J mice are summarized in table 
2. In four experiments, the rate of protection against cerebral 
malaria increased with an increasing number of parasites in the 
immunizing infection, particularly when the challenge infection 
was given 14 days after the immunizing infection. Up to 85% of the 
mice could be protected by this immunization procedure compared 
to 0% in un-immunized controls. When the challenge infection was 
given 9 days after immunization, 85% of the animals given a 105 PE 
immunizing dose and 54% of the animals given a 107 PE immunizing 
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dose were protected against CM. Furthermore, immunization by a 
two-day infection terminated by chloroquine treatment had no 
significant effect on parasitemia during the challenge infection as 
compared to untreated controls. In mice that were not protected 
against CM by this immunization procedure, changes in body 
temperature and day of death after infection were similar to those 
in untreated controls. 
TABLE 2 
EFFECT OF AN IMMUNIZING INFECTION ON THE 
DEVELOPMENT OF CEREBRAL MALARIA 
INFECTION 
DOSE 
103PE 
IO 5 PE 
ΙΟ
7
 PE 
No PE 
MICE PROTECTED AGAINST CEREBRAL MALARIA 
challenge infection (10 PE) given 
9 days I 14 days 
after immunizing infection 
η % 
3 33 
13 85 
13 54 
8 0 
η % 
12 8 
13 85 
19 84 
8 0 
The variation in results after immunization with disrupted 
parasites as compared to high protection rates in mice immunized 
with a two-day infection of live PE suggested that parasite 
proliferation rather than just the presence of parasitic material 
from disrupted PE might, more efficiently, provide stimuli for 
protection to cerebral malaria. In subsequent experiments, the 
effect of parasite products, secreted during in vitro proliferation 
of parasites, on development of protection against cerebral malaria 
was investigated. 
The effect of immunization with exoantigens on cerebral malaria 
The results of experiments in which 5 independently prepared 
batches of exoantigens were tested in C57BI/6J mice, are sum-
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marized in table 3. 
TABLE 3 
EFFECT OF IMMUNIZATION WITH 
DIFFERENT BATCHES OF EXOANTIGEN 
EXOANTIGEN 
0.2 ml exoantigen 
0.4 ml exoantigen 
0.8 ml exoantigen 
0.2ml exoag+adjuvants 
0.2 ml PBS control 
0.2 ml culture control 
1 
8/10 
5/5 
4/5 
3/5 
0/5 
-
2 
2/5 
-
-
-
0/5 
0/5 
Batch 
3 
3/5 
-
-
1/6 
-
4 
3/6 
-
-
0/3 
-
5 
1/5 
-
-
0/3 
-
All data are expressed as number of nice protected against 
cerebral malaria vs. number of immunized mice. 
- not determined 
Neither the amount of exoantigen nor the use of Complete Freund's 
Adjuvants affected the proportion of mice succesfully immunized 
against cerebral malaria. Mice immunized with a preparation of 
normal, uninfected erythrocytes (culture control) were not pro-
tected. The data show that the rates of protection in mice im-
munized against CM with different batches of exoantigens was 
variable. 
Exoantigen ELISA 
The antibody response to exoantigens could only partly predict 
protection against CM (figure 3). Antibody titers higher than those 
observed in untreated controls always correlated with protection 
and this was independent of the method used for immunization 
(infection with a high number of PE, a two-day immunization 
terminated by chloroquine treatment, or immunization with 
exoantigens). In part of the immunized mice protected against CM, 
however, titers were in the range observed in untreated controls. 
Furthermore, in untreated or placebo-treated infected controls that 
did not develop CM the same low titers against exoantigen were 
observed as in the unprotected mice. 
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Figure 3. 
Anti-exoantigen titre in C57BI/6J mice immunized against cerebral malaria (CM). 
Mice were immunized by either infection with a high number of parasites or a 2-day 
immunization period with live parasitized erythrocytes or by injection with 
exoantigen. Antibody titres were determined 7 or 9 days after the immunizing infection 
or 9 days after immunization. The titre against exoantigen is expressed as the 
percentage of the titre found in a pool of malaria-immune mouse serum. 
DISCUSSION 
In previous work (Curfs et a/. 1989), we observed that a timely 
treatment with antibodies from malaria-immune mice injected 
before day 5 after infection prevented the development of cerebral 
malaria in P. berghei-'mfected mice. This suggested the possibility 
of immunization against the development of cerebral malaria (CM). 
The experiments described in this paper, were done to examine the 
use of live or disrupted parasites or parasite products for 
immunization against CM. 
In all of these experiments (immunization with either disrupted PE, 
live PE, or parasite products), protection against the development 
of CM during infection was not associated with inhibition of 
parasite proliferation; therfore, it can be concluded that parasite 
protective and cerebral malaria protective mechanisms are 
probably independent of each other. This supports a similar 
conclusion that protection against CM can be obtained through the 
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use of antibodies collected from malaria-immune mice without an 
effect on parasitemia (Curfs et al. 1989). It is remarkable that an 
immunizing infection with ΙΟ7 PE, freely proliferating for two days 
and then terminated by chloroquine treatment (a period of antigenic 
exposure which might in itself give a strong immunizing signal), 
has no inhibitory effect on the proliferation of the parasite in a 
subsequent challenge with 103 PE. 
An increasing proportion of mice protected against CM after 
infection with an increasing number of parasites in the infectious 
inoculum, as observed in our experiments, may illustrate two 
points. First, development of cerebral malaria does not depend on 
the magnitude of the parasitemia and second, protection may be due 
to timely production of protective antibody early after infection. In 
addition, a two-day immunization with live parasites terminated by 
chloroquine treatment, or immunization with high numbers of 
disrupted parasites, or with exoantigens may provide equally well a 
timely presence of protective antibody. 
Pilot experiments using the same immunization procedures (high 
numbers of parasites for infection or a two-day immunization 
period) were performed using P. berghei ANKA in place of K173. In 
only part of these experiments immunization resulted in a 
significant increase in the proportion of mice protected against CM 
(results not shown). The proportion of mice without CM after an 
untreated infection with P. berghei ANKA, however, is already 
higher than in experiments with P. berghei Kl 73; therefore, making 
it difficult to establish significant effects in the immunization 
against CM in the ANKA model. 
Since the cerebral syndrome can be prevented by a timely 
suppression of T-cell reactivity (Curfs et al. 1989) and parasitemia 
is associated with immunosuppression (Eling, 1982), an increasing 
parasite load early after infection with ΙΟ7 PE may prevent 
development of the syndrome by suppression of T-cell reactivity. A 
similar observation that high rather than low numbers of parasites 
in the infective inoculum protect against cerebral malaria was 
made in P. berghei-infected rats by Kamiyama, Tatsumi, Matsubara 
et al., (1987). 
Protection against CM after pre-immunization with live parasites 
or exoantigens suggests that products secreted by the parasite may 
play a role. Variable results when mice were immunized with 
disrupted parasites may be explained by a variable presence of the 
necessary substance inside the parasite. The necessary sub-
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stance(s) do(es) not accumulate in the parasite, but rather is 
secreted. Experiments on the relation between antibody titers 
against exoantigens and protection against CM are not conclusive. 
Though high antibody titers are associated with protection, low 
titers may or may not be associated with protection. This may 
relate to the fact that exoantigen preparations contain a variety of 
antigens whereas only a fraction may be relevant. Thus, antibodies 
to irrelevant antigens may disturb the picture. In addition, kinetics 
of production of antibodies against exoantigens may be important 
since in previous experiments protection by antibody was more 
effective when given before day 5 after infection (Curfs et al. 
1989). Further analyses are needed. 
The variable results with exoantigen preparations confirm the 
observation of Bate et al. (1989). They too reported variation in the 
capacity of batches to induce anti-exoantigen antibody that can 
prevent the release of Tumor Necrosis Factor (TNF) from macro­
phages by exoantigen in vitro. 
In the P. berghei K173 and ANKA-mouse model, TNF plays an 
important role in the development of cerebral malaria (Grau, 
Fajardo, Piguet et al., 1987; Curfs et al. 1990). Since Bate et al. 
(1989) showed that anti-exoantigen antibody can prevent TNF 
release from macrophages, the question arises whether protection 
against cerebral malaria by immunization with live or disrupted 
parasites depends on the timely presence of anti-exoantigen 
antibody. When this is true, three phenomena need to be explained: 
First, during infection we could enhance the development of 
cerebral malaria by injection of 10 μg rH-TNFa (Curfs et al. 1990) 
but not by injection of exoantigens (unpublished observation). The 
capacity of our exoantigens to release sufficient TNF in vivo to 
enhance CM, however, remains to be determined, although others 
described that their exoantigens can induce TNF release in vivo 
(Bate et al. 1989). Second, we found that antibody from immune 
mice had to be present before day 5 of infection to prevent 
development of CM. If protection by antibody from immune mice 
prevents exoantigen-dependent triggering of cerebral malaria, why 
must it be present early after infection and does not protect when 
given shortly before cerebral malaria is manifested? And third, in 
the work of Bate et al. (1989), IgM antibodies against exoantigens 
are more important than IgG, whereas in our work, we could protect 
against cerebral malaria by IgG from malaria-immune mice. 
Another explanation for the inhibition of CM by antibody from 
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immune mice comes from the observation that an immuno-
pathological T-cell dependent reaction is involved in the 
development of cerebral malaria in P. berghei-infected mice (Clark, 
1987; Curfs et al. 1989; Grau et al. 1987). This T-cell reaction is 
triggered by the parasite or parasite products and the timely 
presence of antibody may prevent this. In this situation presence of 
antibody early after infection is essential (Curfs et al. 1989). 
Further analysis must show whether both mechanisms are 
operative. 
In summary, these results indicate the possibility of immunizing 
against the development of cerebral malaria by using the parasite 
or parasite products. The results are compatible with an antibody-
based mechanism and suggest the possibility of development of a 
vaccine against cerebral malaria. 
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SUMMARY 
The effect of TNF injection on malaria-infected mice was studied. 
C57BI/6J mice infected with Plasmodium berghei K173 exhibited 
an increased sensitivity to exogenous Tumour Necrosis Factor-α 
(TNF). Injection of 1 5 цд TNF was lethal to some of the animals 
when given 5 to 7 days after infection, while when given later in 
the infection (i.e. day 8 to 10) amounts as low as 2.5 цд TNF 
appeared to be lethal in all mice. The pathology in infected mice 
treated with TNF resembled that found in the brains of infected 
mice dying with cerebral malaria. Infected mice treated with TNF, 
however, also developed severe pathological changes in other 
organs. On the contrary, treatment with sub-lethal amounts of TNF 
(1.0 μg or less) given on day 8 and 9 after infection, protected mice 
against the development of cerebral malaria. 
In addition, infected mice exhibited an enhanced sensitivity for 
treatment with lipopolysaccharide (LPS). Sub-lethal amounts of 
LPS, however, did not prevent mortality as in TNF-treated mice 
(LPS-treated mice died at about the same time as infected mice 
that developed cerebral malaria), but no cerebral haemorrhages 
were found in the majority of LPS treated, infected animals. 
Treatment with dexamethasone during infection protected mice 
against the development of cerebral malaria, but did not suppress 
their increased sensitivity to exogenous TNF. 
Treatment of mice with liposome encapsulated dichloromethylene 
diphosphonate (lip-CI2MDP), used to eliminate macrophages (an 
important source of TNF), prevented the development of cerebral 
malaria, but only when given before day 5 of infection. Mice 
protected by treatment with lip-CI2MDP, however, remained 
sensitive for LPS on the eighth day of infection. 
INTRODUCTION 
TNF seems to play a dual role: on the one hand, much of the 
pathology found during severe malaria (Clark 1987a; Clark, 
Cowden, Butcher et al., 1987) is considered to be mediated by 
Tumour Necrosis Factor-α (TNF), while on the other hand, TNF 
treatment can mediate protection against malaria (Clark, Cowden 
& Butcher, 1990; Stevenson, Tarn & Nowotarski, 1990; Clark, Hunt, 
Butcher et al., 1987). 
Both human and murine malaria parasites elicit a TNF response in 
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invaded hosts (Grau, Fajardo, Piguet et al., 1987; Del Giudice, Grau 
& Lambert, 1988) and cerebral malaria has been attributed to the 
overproduction of cytokines, particularly TNF (Grau, Bieler, 
Pointaire et al., 1990). In South-East Asia cerebral malaria is 
accompanied by severe pathology in different organs whereas in 
cerebral malaria in African children pathology in other organs is 
usually absent (Warrell, Molyneux & Beales 1990). In P. berghei 
ANKA infections, cerebral pathology is the only pathology found 
and can be prevented by treatment with antibody to TNF (Grau et 
al., 1987) or by suppression of monocytopoiesis (Grau, Kindler, 
Piguet et al., 1988). Pathology otherwise found in association with 
severe P. vinckei vinckei malaria (hypothermia, liver necrosis, but 
not cerebral malaria), is provoked by the injection of TNF into 
infected animals at an early stage of the disease (Clark, llschner, 
MacMicking et al., 1990). Therefore, treatment that suppresses TNF 
production may prevent malarial pathology, including cerebral 
malaria. 
This paper describes the effects of: (1) TNF, (2) LPS, (a strong 
inducer of TNF production by macrophages) (Gifford & Lohmann-
Matthes, 1987), (3) dexamethasone, (an inhibitor of TNF production 
by macrophages) (Beutler, Krochin, Milsark et al., 1986), and (4) 
liposomal dichloro-methylene diphosphonate (lip-CI2MDP, depletes 
macrophages) (van Rooijen, 1989; van Rooijen, Kors & Kraal, 1989) 
on enhancement or suppression of cerebral malaria in P. berghei 
K173-infected mice. 
MATERIALS AND METHODS 
Mice: female C57BI/6J mice, aged 6-10 weeks, were used from 
colonies maintained at the Central Animal Facility of the 
University of Nijmegen, or were obtained from the 
Bundesgezundheidsamt, Berlin, Germany. All mice were housed 
under specific pathogen-free conditions in plastic cages and 
received water and standard RMH food (Hope Farms, The 
Netherlands) ad libitum. 
Parasite: Plasmodium berghei K173 was maintained by weekly 
transfer of parasitized erythrocytes (PE) from infected into naive 
mice. Experimental mice were infected intraperitoneally with 103 
PE from blood of infected donor animals of the same strain and sex. 
Plasmodium berghei ANKA was a liquid-N2 frozen stabilste 
obtained from Dr. G. Grau, Geneva, Switzerland. Experimental mice 
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received 2x105 PE from the first passage of a frozen stabilate. 
Parasitemia: thin blood films were made from tail-blood, stained 
with May-Grünwald and Giemsa's solutions, and the proportion of 
red blood cells infected with the parasite determined. 
Cerebral malaria: the majority of C57BI/6J and C57BI/Rij mice 
infected with P. berghei K173 die early in the second week after 
infection. Shortly before death a severe hypothermia develops 
which is strongly correlated with development of haemorrhages in 
the brain (Curfs, Schetters, Hermsen et al., 1989). Mice that 
survive this critical period only show a limited, transient 
hypothermia and die in the third week after infection or later 
without any noticeable cerebral pathology. 
Body temperature: to measure body temperature, the probe of a 
Technoterm digital thermometer (Thermotex, The Hague, The 
Netherlands) was inserted in the rectum and read after 18 seconds. 
Histology: Brains, and in some cases spleen, liver and lungs, were 
removed post-mortem or from mice sacrificed during the 
experiment. For light microscopy tissues were fixed in Carnoy's 
fluid for 4 hours and subsequently stored in 70% ethanol. Using 
routine histological procedures, paraffin sections (thickness 5 цгп) 
were stained with Goldners trichrome or PAS-haematoxylin stain. 
For electronmicroscopy pieces of tissue were immersed in 2% 
glutaraldehyde in phosphate buffer (0.1 M, pH 7.4) and dissected 
into pieces of approximately 1x1x1 mm. Fixation was continued for 
2 hours after which time the fixative was replaced with phosphate 
buffer. The material was post-fixed for one hour in 2% osmium 
tetroxide in phosphate buffer, washed, dehydrated, then embedded 
in Epon. Semi-thin sections (1 μπι) were Paragon-stained and 
examined by light microscopy. 
Recombinant Human Tumour Necrosis Factor-α (TNF) was obtained 
from Boehringer-lngelheim (FRG). In all experiments TNF was 
diluted in pyrogen-free saline and injected intravenously. 
Dichloromethylene diphosphonate (CI2MDP) was obtained from 
Boehringer-Mannheim (FRG) and liposomal CI2MDP (lip-CI2MDP) was 
prepared as described before (van Rooijen, 1989). A volume of 0.2 
ml, containing approximately 1 mg of CI2MDP, was injected 
intravenously/mouse/injection. 
Dexamethasone (9a-fluoro-16a-methylprednisolone) was obtained 
from Sigma and dissolved in tap water for 24 hours at a 
concentration of 10 mg/l (stock solution). The stock solution and 
the drinking bottles on the cages containing dexamethasone were 
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wrapped in aluminum foil to protect the solution from oxidation by 
light. Drinking water was changed twice weekly. Assuming a water 
intake of 3 ml/day, the addition of 1, 5 or 10 mg dexa-
methasone/liter drinking water resulted in an intake of 1 50, 750 
or 1500 цд/kg body weight/day, respectively. 
Bacterial lipopolysaccharide (E. coli phenol extract) was obtained 
from Sigma (L-3129), dissolved in pyrogen-free saline and 
injected intraperitoneally. 
Mini-osmotic pumps (Alzet model 2001, Alza, Palo Alto) were 
filled with LPS dissolved in pyrogen-free saline in order to deliver 
a calculated amount of 10 цд LPS/24 hours. These pumps were 
inserted intraperitoneally one day before infection and had an 
expected delivery period of 10.5 days according to the 
manufacturer's information. 
RESULTS 
TNF treatment and the cerebral syndrome 
Uninfected mice injected with up to 100 цд TNF did not develop 
hypothermia after injection and did not die (results not shown). 
However, when TNF was injected into P. berghei-'mfected C57 
BI/6J mice, hypothermia developed and mice died within 24 hours, 
depending on the dose and day of injection. In the first week after 
infection, injection of 15 цд of TNF resulted in hypothermia and 
death within 24 hours in part of the mice. In the second week after 
infection, all mice injected with 15 цд of TNF developed hypo­
thermia and died within 24 hours. Even lower amounts of TNF (i.e. 5 
цд on day 8 or 9, or 2.5 цд on day 9) had the same effects (table 1 ). 
Histopathological analysis of the brains of infected mice 
sacrificed 2 hours after injection of 15 цд TNF revealed petechial 
haemorrhages, (fig. 1A) that were similar to those found in mice 
developing cerebral malaria (Curfs et al., 1989; Curfs, van der 
Meer, Sauerwein et al., 1990). In addition, in TNF-treated infected 
mice tubular necrosis was found in the kidneys (fig. IB) and 
margination of leucocytes was found in the venous part of the 
vascular system in the lungs (fig. 1С), as well as in the liver (not 
shown). In the liver single cell necrosis of parenchymal cells, 
predominantly in the midzonal area was observed (fig. ID). These 
midzonal changes in the liver can also be found in mice that die 
with an otherwise untreated cerebral malaria, though coagulative 
63 
necrosis in this area has been observed too (result not shown). 
These changes were also found by Clark et al. (Clark & Clouston 
1980; Clark, Cowden, Butcher et al. 1987) in P. vinckei-infected 
CBA/CaH mice after treatment with TNF although they appeared 
somewhat later (6-8 hours after TNF injection). Post-mortem 
analysis of P. berghei-infected animals that died after TNF 
treatment showed histopathological findings similar to those 
observed in sacrificed mice. 
Table 1. 
THE EFFECT OF TNF-INJECTION ON P. SERGHEHNFECTED 
MICE 
day of treatment amount TNF η hypothermia mortality 
5 
6 
7 
8 
9 
10 
day 8 + 9 # 
injected 
15цд 
15 цд 
15цд 
0.2 ml saline 
15 цд 
10 цд 
5цд 
15 цд 
5 цд 
2.5 цд 
15цд 
0.25 + 0.5 цд 
0.5 + 1.0 цд 
3 
3 
4 
5 
7 
1 
1 
2 
3 
3 
3 
3 
3 
after iniection within 24 hrs 
2/3 
3/3 
4/4 
0/5 
7/7 
1/1 
1/1 
2/2 
3/3 
3/3 
3/3 
2/3 
0/3 
1.6°C±0.6 
3.0°С±1.6 
2.6°C+0.1 
5.8°С±1.0 
1/3 
0 / 1 * 
3/4 
0/5 
5/5* 
1/1 
1/1 
2/2 
3/3 
3/3 
1/1* 
2/3 
0/3 
Untreated controls (n=10) died between day 10 and 12 after infection. 
* two mice were sacrificed for histopathological analysis. 
# multiple injections. 
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Figure 1 
Histopathology of infected mice treated with 1 5 цд TNF. Brains and several internal 
organs were removed and prepared for light or electron microscopy. 
A. Cerebral hemorrhage in the brain of a mouse sacrificed 2 hours after treatment 
with TNF on day 10 after infection (Goldner stain, mag. 450x). 
B. Tubular necrosis in the kidney of a mouse 2 hours after treatment with TNF on day 
10 after infection (Paragon stain, mag. 450x). 
С Margination of leucocytes in the vasculature of the lung of a mouse 2 hours after 
treatment with TNF on day 8 after infection (Paragon stain, mag. 450x). 
D. Necrosis of parenchymal cells of the liver in a mouse 2 hours after treatment with 
TNF on day 10 after infection (Paragon stain, mag. 450x). 
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Sensitivity to TNF treatment increased during infection as 
indicated by an increased mortality occurring earlier after 
treatment and even after lower doses of TNF (table 1). When 2.5 цд 
of TNF or more was injected on day 8 or later during infection all 
mice died within 24 hours. Though there were small differences in 
the time of death after TNF-injection, the development of lethargy, 
locomotor disturbances and hypothermia was enhanced after 
injection of TNF at later time-points. Body temperature was 
measured 2 hours after injection with 15 цд of TNF (Table 1 ). Only 
data of day 10 are significantly higher (Student's t-test). 
Infected mice that received 15 цд of TNF and did not die within 24 
hours (some of the mice treated on day 5, 6 and 7 after infection, 
table 1), did not develop hypothermia. They died in the period days 
9-12 after infection, like untreated or saline-treated controls, 
having developed cerebral lesions as shown by histological 
examination of their brains. 
Injection of 0.25 ид or 0.5 цд of TNF on day 8 did not induce hypo­
thermia. An additional injection of 0.5 цд of TNF on day 9 in mice 
that had received 0.25 цд of TNF on day 8 of infection induced 
hypothermia in two of three mice which died on day 11 and 12, 
respectively, having cerebral haemorrhages. The third mouse did 
not show any hypothermia and died on day 19 after infection 
without cerebral malaria (post-mortem analysis). Mice receiving 
an additional injection of 1.0 цд of TNF on day 9 (having received 
0.5 цд of TNF on day 8) did not develop hypothermia. These mice 
died 26, 28 and 28 days after infection and did not exhibit cerebral 
pathology (post-mortem analysis). 
The effect of LPS injection on development of the cerebral 
syndrome 
Since LPS is a strong inducer of TNF production by macrophages the 
effect of LPS injection on development of the cerebral syndrome 
was determined. Macrophages stimulated by LPS were refractory to 
the production of TNF after an additional stimulus within a period 
of one week (Gifford & Lohmann-Matthes, 1987). Thus, infected 
mice received sub-lethal amounts of LPS early during infection 
aiming to prevent the development of cerebral malaria later. 
Uninfected mice treated with 500 цд of LPS or more all died within 
24 hours, whereas only 1 of 3 mice treated with 250 цд of LPS, and 
none of the mice treated with amounts lower than 150 цд of LPS, 
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died. All mice injected with 250 цд of LPS or more developed 
hypothermia which increased progressively in animals that died 
within 24 hours (results not shown). 
The effect of LPS treatment of infected mice on the development 
of characteristics of the cerebral syndrome is described in table 2. 
Table 2. 
THE EFFECT OF LPS-INJECTION ON P. ßEKGHEHNFECTED 
MICE 
day p.i. 
Exp. 1 
amount LPS 
125 цд 
100 цд 
75 цд 
50 цд 
10 цд 
saline 
hypothermia 
+ (3.1 °С) 
+ (2.6°С + .3) 
+ (3.8 °С) 
+ (1.б°С) 
+ (1.б°С) 
- (0.1 °С) 
mortality (dav) 
2 hrs after LPS 
9* 
8, 9, 9* 
11 
10 
12 
10, 11, 11, 
11, 11 
11 
hemorrh. 
Δ 
" 1 " » ™ 
Δ 
Δ 
Δ 
Δ 
η 
1 
3 
1 
1 
1 
6 
Exp. 2 
8 10 цд 
-1 daily 50 цд 
-1 10 цд/24 hrs, pumps 
-1 daily saline 
Δ = not done. 
Δ 
Δ 
Δ 
Δ 
9,10,10 +,-,-
9,11,12 -,-,Δ 
10, 10, 16 -,-,+ 
8,8,9,9,9,18 +,+,+, 
+, Δ,-
3 
3 
3 
6 
mice dying within 24 hours after injection. 
In the first experiment, injection of 10 цд or more of LPS given on 
day 8 after infection caused hypothermia and injection of 100 or 
125 цд of LPS was lethal within 24 hours. These results indicate 
that during infection mice are more sensitive to LPS. All mice died 
in the second week after infection like the saline-treated controls 
did, but development of brain lesions was either absent or not 
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determined (table 2). 
In a second experiment (table 2), single LPS treatment was 
compared to daily injections or continuous release of LPS from 
osmotic pumps. In this experiment, brain histology (post-mortem) 
was performed to assess an effect of LPS injection on the 
development of haemorrhages. Although LPS treatment did not 
change the survival period after infection, it prevented brain 
pathology in 6 out of 8 mice that died in the period when saline-
treated controls died with cerebral haemorrhages. 
Thus, LPS treatment prevented development of cerebral malaria in 
the majority of mice but it did not prevent mortality in the second 
week after infection. 
The effect of dexamethasone treatment on infection 
Dexamethasone inhibits TNF production of macrophages (Beutler, 
Krochin, Milsark et al., 1986). Therefore, infected mice received 
dexamethasone in their drinking water to test its effect on 
development of cerebral malaria. Dexamethasone treatment was 
started one day before infection. In comparison to infected 
controls, treatment with 5 or 10 mg dexamethasone/litre drinking 
water, corresponding to an approximate daily intake of 0.75 or 1.5 
цд/kg body weight, prevented hypothermia and mortality in the 
second week after infection (figure 2). 
6 8 10 12 14 16 18 20 22 
DAYS AFTER INFECTION 
6 8 10 12 14 16 18 20 22 
DAYS AFTER INFECTION 
Figure 2. 
Effect of different concentrations of dexamethasone in drinking water (mg/l) of 
C57BI/6J mice infected intraperitoneal^ with 1000 parasitized erythrocytes. 
Dexamethasone treatment was started one day before infection. The error bars 
represent the standard deviation. 
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Furthermore, cerebral pathology was prevented as determined by 
post-mortem histology. Infected mice receiving 1 mg dexa-
methasone/litre drinking water developed cerebral malaria similar 
to infected untreated controls. 
Dexamethasone treatment inhibited parasitemia and this was found 
to be statistically significant on day 9 and later after infection i t-
test). 
In the same experiment, it was investigated whether dexa­
methasone treatment decreased sensitivity of infected C57BI/6J 
mice to exogenous TNF. Randomly selected mice from the 
dexamethasone-treated groups (2.5, 5 or 10 mg/l), as well as the 
infected control mice, received 15 цд of TNF on different days 
after infection. Results of this experiment are depicted in table 3. 
Table 3 
THE EFFECT OF DEXAMETHASONE TREATMENT ON 
TNF-DEPENDENT ENHANCEMENT OF CEREBRAL MALARIA 
dose dexa 15 цд TNF (day p.i.) hypothermia mortality (day p.i.) 
2.5 mg/l 
5 mg/l 
10 mg/l 
normal drinking 
water 
7 
θ 
9 
12 
-
7 
8 
9 
12 
-
7 
8 
12 
-
7 
8 
9 
. 
+ 
+ 
+ 
-
-
+ 
+ 
+ 
-
+ 
+ 
+ 
-
+ 
+ 
+ 
21 
21 
9 
12 
23 
21 
9 
10 
12 
26 
7 
8 
12 
21 
7 
8 
9 
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All infected controls developed the cerebral syndrome after 
treatment with 15 цд of TNF and all infected mice treated with 
dexamethasone (2.5, 5 or 10 mg/l) alone did not develop the 
cerebral syndrome as expected (table 3, see also above). 
The cerebral syndrome was not provoked after injection of 15 цд of 
TNF either on day 7 or 8 in mice receiving 2.5 mg or on day 7 in a 
mouse receiving 5 mg of dexamethasone/l of drinking water. In all 
other cases, TNF injection provoked the cerebral syndrome as 
confirmed by histological examination of their brains. Thus, 
dexamethasone treatment prevented development of cerebral 
malaria, but a reduced TNF-sensitivity was only observed when 
TNF was injected on day 7 or 8 after infection. 
The effect of lip-CI2MDP on the development of cerebral malaria 
Intravenous treatment of mice with lip-CI2MDP effectively 
depletes macrophages from the spleen and Kupffer cells from the 
liver (van Rooijen, 1989; van Rooijen & Claassen, 1988). The effect 
of lip-CI2MDP treatment before or during infection on the 
development of cerebral malaria was analyzed. The results of 
these experiments are summarized in table 4. 
Lip-CI2MDP given on or before day 5 after infection prevented 
development of the cerebral syndrome in some of the mice. 
Repeated injections of lip-CI2MDP (i.e. on day -1 and +4 relative to 
infection) did not improve the results. Treatment with lip-CI2MDP 
on day 7 or later did not prevent cerebral malaria. Mice protected 
against the cerebral syndrome did not develop hypothermia in 
contrast to animals that were not protected (results not shown). 
Post-mortem analysis showed that all mice dying in the second 
week after infection exhibited cerebral haemorrhages irrespective 
of treatment with lip-CI2MDP treatment. 
In addition, the effect of lip-CI2MDP on LPS sensitivity was 
determined. Mice treated with lip-CI2MDP one day before infection 
remained sensitive to the lethal effect of 100 цд LPS given on day 
8 after infection, similar to saline-treated and infected controls; 
all LPS-treated mice died within 24 hours after injection. 
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Table 4 
THE EFFECT OF LIP-CI2MDP TREATMENT ON THE 
DEVELOPMENT 
OF CEREBRAL MALARIA IN P. ß£/?GHE/-INFECTED MICE 
day 
-1 
+1 
+3 
-1 and +4 
-1 and +4 
+4 
+5 
+7 
+8 
-1 
-1 
+1 
+5 
-1 
+8 
-1 
+8 
treatment η 
lip-CI2MDP 
lip-CI2MDP 
lip-CI2MDP 
lip-CI2MDP 
lip-CI2MDP 
lip-CI2MDP 
Np-CI2MDP 
lip-CI2MDP 
lip-CI2MDP 
no 
saline 
saline 
saline 
saline 
lip-CI2MDP & 
100 цд LPS 
saline & 
100
 ц
д LPS 
о cerebr 
8/14 
2/3 
2/3 
2/3 
1/4* 
3/6* 
2/10 
0/3 
0/1 
0/4* 
0/5* 
0/6 
0/3 
1/4 
0/3 
0/3 
* experiments with P. berghei ANKA 
DISCUSSION 
Plasmodium berghei K173 infection in mice leads to the adhesion 
of leucocytes to the endothelial wall of cerebral capillaries and 
post-capillary venules (Polder, Eling, Curfs et al., 1992) and 
cerebral haemorrhages (Curfs et al., 1989; Polder, Jerusalem & 
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Eling, 1983), resulting ¡η death ¡η the second week after infection. 
Approximately 12 to 24 hours before death, mice develop severe 
hypothermia. Development of cerebral lesions in P. berghei ANKA 
infected CBA mice is closely related to monocytopoiesis and 
excessive TNF production (Grau et al., 1987, 1988; Clark, lischer, 
MacMicking et al., 1990). TNF increases the adhesiveness of the 
endothelium for leucocytes (Bevilaqua, Stengelin, Gimbrone et al., 
1989) and activates endothelial cells (Piguet, Grau & Vassalli, 
1990). Both effects can lead to the development of vascular 
lesions. Why in murine cerebral malaria this is more pronounced in 
the vasculature of the brain remains unclear. Lesions in the brain 
may rapidly lead to death before damage to other organs has fully 
developed. In our studies, the injection of TNF in infected mice 
caused hypothermia and development of cerebral lesions, though 
pathology was observed in other organs as well. Kettelhut, Fiers, 
Goldberg (1987) found that injection of 4 μg of TNF/g body weight 
caused hypothermia in normal rats and Dinarello, Cannon, Wolff et 
al. (1986) suggested that TNF had a direct effect on the thermo-
regulative center of the brain. Our data show that 2.5 цд of TNF (i.e. 
0.1 цд/д body weight) or more cause a strong hypothermia 
indicating that infected mice are more sensitive to this TNF 
effect. The strongly enhanced monocytopoiesis during infection 
leads to an increasing pool of cells capable of producing increasing 
amounts of TNF after stimulation. This is in line with the 
observation that administration of TNF causes induction and 
release of endogenous TNF as well as an increased expression of 
TNF receptors and cellular adhesion molecules e.g. on endothelial 
cells (Bevilaqua et al., 1989; Le & Vilcek, 1987; Pohlmann, 
Stannes, Beatty et al., 1986). The sequestration of leucocytes in 
parts of the venous vascular system in association with TNF 
treatment (figure 1) and cerebral lesions (Polder et al., 1992) 
further supports the role of excessive TNF production in the 
development of cerebral lesions, already suggested by Grau et al. 
(1987), Grau, Piguet, Vassalli et al. (1989), and Grau, Heremans, 
Piguet et al. (1989) in a P. berghei ANKA model, and which also 
explains development of lesions in other organs (figure 1 ). The 
injection of TNF in P. berghei K173 infected mice not only leads to 
cerebral pathology, as observed in mice developing cerebral 
malaria, but additionally leads to pathological changes in the 
spleen, liver and lung, changes comparable to the pathology 
observed in infected mice that do not develop cerebral lesions 
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(ENng, van Zon & Jerusalem, 1977). Furthermore, pathology in 
organs other than the brain resembles that found in terminal P. 
falciparum malaria in humans e.g. in South East Asia. In this 
respect, P. berghei Kl 73 infection in mice differs from P. berghei 
ANKA infection where cerebral lesions are the main pathology 
found, and lacks many of the systemic changes found in P. 
falciparum malaria according to Clark, MacMicking, Gray et al. 
(1992). TNF injection in P. w'nclteHnfected mice was reported to 
produce systemic changes found in human malaria, but did not 
cause cerebral lesions (Clark, Cowden, Butcher et al. 1987, Clark 
et al., 1992). Therefore, P. berghei K173 infection in C57BI/6J 
mice provides a good model for studying human falciparum malaria. 
In comparison to normal mice, malaria-infected mice are more 
sensitive to LPS treatment, causing a dose-dependent enhanced 
morbidity and mortality (Clark 1987b). Since LPS is a strong 
inducer of TNF (Carswell, Ols, Kassel et al. 1975), the effect of 
LPS treatment on enhancement of the cerebral syndrome was 
determined. Depending on the dose and day of infection, LPS 
treatment caused hypothermia and death as expected. LPS-
stimulated macrophages are refractory to the production of TNF 
upon an additional stimulus given within a one week's period 
(Gifford et al., 1987). This suggested treatment of infected mice 
with sub-lethal amounts of TNF or LPS to trigger early release of 
TNF and refractoriness before concentrations of TNF critical to 
development of cerebral malaria are reached. Repeated injections 
of sub-lethal amounts of both TNF and LPS or continuous release of 
LPS prevented development of haemorrhages, but LPS treatment did 
not prevent death in the second week of infection. Desensitization 
to the lethal effects of TNF (Wallach, Holtmann, Engelmann et al., 
1988) might explain why sub-lethal amounts of TNF or LPS prevent 
development of cerebral lesions, but leaves open to speculation 
why LPS treated animals die early. Although LPS pathology is 
usually associated with macrophage activation, Groeneveld, 
Claassen, Kuper et al. (1988) found severe LPS-dependent 
pathology in mice depleted of their Kupffer cells and spleen 
macrophages, eliminating an important source of TNF. Whether this 
macrophage-independent effect of LPS explains death of LPS-
treated mice in the absence of cerebral lesions remains to be 
determined. 
Treatment with dexamethasone inhibits TNF production when 
started before the synthesis of TNF-mRNA (Beutler et al., 1986). 
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Treatment with dexamethasone prevented hypothermia, death in 
the second week and cerebral lesions supporting earlier 
observations (Curfs et al., 1989; Eling, 1980). Dexamethasone-
treated mice, however, remained sensitive to treatment with 
exogenous TNF, causing hypothermia and cerebral lesions. TNF-
receptor expression is upregulated by IFN-γ (Tsujimoto, Yip & 
Vilcek, 1986) and IFN-γ production is increased during malaria 
infection (Shear, Srinivasan, Nolan et al., 1989) and plays an 
important role in the development of cerebral malaria (Grau, 
Heremans, Piguet et al., 1989). Treatment with rH-TNF may 
therefore also exert its pathological effect through TNF receptors 
expressed on endothelial cells and in the absence of endogenous 
TNF production. How dexamethasone treatment inhibits para­
sitemia is unknown. Reduction of erythropoiesis by dexamethasone 
may inhibit parasitemia because of the parasite's preference for 
reticulocytes, however we could not observe any effect of 
dexamethasone on blood reticulocyte numbers and neither did 
Franz, Lim, Baze et al. (1988) in the hamster-cheeck pouch 
cerebral malaria model. 
The important role of macrophages and TNF in the pathogenesis of 
cerebral lesions (Grau et al., 1988) prompted a study on the effect 
of macrophage depletion on development of cerebral malaria. The 
elimination of macrophages from the spleen and Kupffer cells from 
the liver after treatment with lip-CI2MDP is well-established (van 
Rooijen, 1989, 1992; van Rooijen, Kors, Kraal 1989). Lip-CI2MDP 
treatment before day 5 after infection prevented the development 
of the cerebral syndrome, in some of the mice, and treatment on or 
after day 5, was completely ineffective. The effectiveness of lip-
CI2MDP treatment before or early after infection may be explained 
in either of two ways. 
First, it is in line with the observation that cerebral malaria can 
be prevented by suppression of monocytopoiesis by treatment with 
anti-IL-3 and anti-GM-CSF from the beginning of the infection 
(Grau et al., 1988). Second, since development of cerebral malaria 
depends on T-cell activation (Curfs et al., 1989; Grau, Piguet, 
Engers et al., 1986) and can be prevented by an early treatment 
with antibody from malaria-immune mice (Curfs et al., 1989), 
macrophage depletion may also prevent antigen processing/ 
presentation necessary for the stimulation of the immuno-
pathological T-cell reaction. 
Why lip-CI2MDP treatment after day 5 is ineffective is not clear. It 
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must be analysed whether macrophages activated by the ingestion 
of parasites or their products no longer phagocytose lip-CI2MDP 
and escape depletion as suggested by the work of Schwarzer, 
Turrini, Ulliers et al(1992). Furthermore, TNF is not only produced 
by monocytes and macrophages, but also by other hematopoietic 
cells (Kinkhabwala, Sehajpal, Skolnik et al., 1990; Sung, Bjorndahl, 
Wang et al., 1988; Rubin, Anderson, Sullivan et al., 1986) which are 
not eliminated by lip-CI2MDP treatment. 
There is a clearly established role for macrophage-derived TNF in 
the development of cerebral malaria in P. berghei ANKA infected 
mice (Grau et al., 1988) which is supported by observations in 
human cerebral malaria patients (Kern, Hemmer, Van Damme et al., 
1989; Kwiatkowski, Hill, Sambou et al., 1990). These results are 
the basis for pilot experiments using anti-TNF antibodies in the 
treatment of human cerebral malaria. Interference with the 
production of macrophage-derived TNF, however, does not always 
prevent cerebral malaria in a P. berghei K173 infection in mice. 
Mice protected by lip-CI2MDP treatment against cerebral malaria 
remain sensitive to treatment with LPS, again suggesting that 
LPS-dependent pathology is partly independent of macrophages, as 
was already observed in uninfected mice treated with lip-CI2MDP (Groeneveld et al., 1988). 
AKNOWLEDGEMENTS 
The authors thank G. Poelen and T. van den Ing for biotechnical assistance and C. 
Celluzzi for reading the manuscript. This work was supported by the Dutch Foundation 
for Fundamental Biological Research (BION-NWO). 
REFERENCES 
Beutler, В., N. Krochin, I. W. Milsark, D. Luedke and A. Cerami (1986). 
Control of cachectin (tumor necrosis factor) synthesis: Mechanisms of endotoxin 
resistance. 
Science 232: 977-980. 
Bevilacqua, Μ. Ρ, S. Stengelin, M. A. Gimbrone Jr. and B. Seed (1989). 
Endothelial leukocyte adhesion molecule 1: an inducible receptor for neutrophils 
related to complement regulatory proteins and lectins. 
Science 243: 1160-1165. 
Carswell, Ε. Α., L J. Old, R. L Kassel, S. Green, N. Fiore and В. Williamson (1975). 
An endotoxin-induced serum factor that causes necrosis of tumors. 
Proc. Nat. Acad. Sci. USA 72: 3666-3670 
75 
Clark, I. A. (1987a). 
Monokines and lymphokines in malarial pathology. 
Ann. Trop. Med. Paras. 81: 577-585. 
Clark, I. A. (1987b). 
Does endotoxin cause both the disease and parasite death in acute malaria and 
babesiosis ? 
Lancet ii: 75-77. 
Clark, I. A. and W. M. Clouston (1980). 
Effects of endotoxin on the histology of intact and athymic mice infected with 
Plasmodium vinckei petten. 
J. Pathol. 131: 221-233. 
Clark, Ι. Α., W. B. Cowden and G. A. Butcher (1990). 
TNF and inhibition of growth of Plasmodium falciparum. 
Immunol. Letters 25: 175-178. 
Clark, Ι. Α., W. B. Cowden, G. A. Butcher and N. H. Hunt (1987). 
Possible roles of tumor necrosis factor in the pathology of malaria. 
Am. J. Pathol. 129: 192-199. 
Clark, Ι. Α., Ν. Η. Hunt, G. A. Butcher and W. B. Cowden ( 1987). 
Inhibition of murine malaria (Plasmodium chabaudi) in vivo by recombinant 
interferon-γ or tumor necrosis factor, and its enhancement by butylated hydroxy-
anisole. 
J. Immunol. 139: 3493-3496. 
Clark, Ι. Α., S. Ilschner, J. D. MacMicking and W. B. Cowden (1990). 
TNF and Plasmodium toerg/iez-ANKA-induced cerebral malaria. 
Immunol. Letters. 25: 195-198. 
Clark, Ι. Α., J. D. MacMicking, K. M. Gray, K. A. Rockett and W. B. Cowden (1992). 
Malaria mimicry with tumor necrosis factor: contrasts between species of murine 
malaria and Plasmodium falciparum. 
Am. J. Pathol. 140: 325-336. 
Curfs, J. H. A. J., T. P. M. Schetters, С. С. Hermsen, С. R. Jerusalem, A. A. J. С Van Zon 
and W. M. С Eling (1989). 
Immunological aspects of cerebral lesions in murine malaria. 
Clin. Exp. Immunol. 75: 136-140. 
Curfs, J. H. A. J., J. W. M. van der Meer, R. W. Sauerwein and W. M. С. Eling (1990). 
Low dosages of interleukin 1 protect mice against lethal cerebral malaria. 
J. Exp. Med. 172: 1287-1291. 
Del Giudice, G., G. E. Grau and P.-H. Lambert (1988). 
"Host responsiveness to malaria epitopes and ¡mmunopathology." 
In: Malaria immunology, (eds. P. Perlmann, and H. Wigzell), pp. 288-330, Karger, 
Basel. 
76 
Dinarello, С. Α., J. G. Cannon, S. M. Wolff, H. A. Bemheim, B. Beutler, A. Cerami, I. S. 
Figari, A. Palladino Jr. and J. V. O'Connor (1986). 
Tumor necrosis factor (cachectin) is an endogenous pyrogen and induces production of 
¡nterleukin-1. 
J. Exp. Med. 163: 1433-1450. 
Eling, W. M. С (1980). 
Role of the spleen in morbidity and mortality of a Plasmodium berghei infection in 
mice. 
Infect. Immun. 30: 634-640. 
Eling, W. M. C, A. A. J. С van Zon and С R. Jerusalem (1977). 
The course of a Plasmodium berghei infection in six different mouse strains. 
Zeitschrift für Parasitenkd. 54: 29-45. 
Franz, D. R., T. S. Lim, W. B. Baze, S. Arimbalam, M. Lee and G. E. Lewis Jr. (1988). 
Pathologic activity of Plasmodium berghei prevented but not reversed by 
dexamethasone. 
Am. J. Trop. Med. Hyg. 38: 249-254. 
Gifford, G. E. and M.-L Lohmann-Matthes (1987). 
Gamma-interferon priming of mouse and human macrophages for induction of tumor 
necrosis factor production by bacterial lipopolysaccharide. 
J. Natl. Cancer Inst. 78:, 121-124. 
Grau, G. E., G. Bieler, P. Pointaire, S. De Kossodo, F. Tacchini-Cotier, P. Vassalli, P. F. 
Piguet and P.-H. Lambert (1990). 
Significance of cytokine production and adhesion molecules in malarial 
immunopathology. 
Immunol. Letters 25: 189-194. 
Grau, G. E., L. F. Fajardo, P.-F. Piguet, B. Allet, P.-H. Lambert and P. Vassalli 
(1987). 
Tumor necrosis factor (cachectin) as an essential mediator in murine cerebral 
malaria. 
Science 237: 1210-1212. 
Grau, G. E., H. Heremans, P.-F. Piguet, P. Pointaire, P.-H. Lambert, A. Billiau and P. 
Vassalli (1989). 
Monoclonal antibody against interferon-γ can prevent experimental cerebral malaria 
and its associated overproduction of tumor necrosis factor. 
Proc. Natl. Acad. Sci. USA. 86: 5572-5574. 
Grau, G. E., V. Kindler, P.-F. Piguet, P.-H. Lambert and P. Vassalli (1988). 
Prevention of experimental cerebral malaria by anticytokine antibodies. 
J. Exp. Med. 168: 1499-1504. 
Grau, G. E., P.-F. Piguet, H. D. Engers, J. A. Louis, P. Vassalli and P.-H. Lambert 
(1986). 
L3T4+ T-lymphocytes play a major role in the pathogenesis of murine cerebral 
malaria. 
77 
J. Immunol. 137: 2348-2354. 
Grau, G. E., Р.-F. Piguet, P. Vassalli and P.-H. Lambert (1989). 
Involvement of tumor necrosis factor and other cytokines in immune-mediated 
vascular pathology. 
Int. Arch. Allergy Appi. Immunol. 88: 34-39. 
Groeneveld, P. H. P., E. Claassen, С F. Kuperand N. van Rooijen (1988). 
The role of macrophages in LPS-induced lethality and tissue injury. 
Immunol. 63: 521-527. 
Kern, P., С J. Hemmer, J. Van Damme, H.-J. Gruss and M. Dietrich (1989). 
Elevated tumor necrosis factor alpha and interíeukin-6 serum levels as markers for 
complicated Plasmodium falciparum malaria. 
Am. J. Med. 87: 139-143. 
Kettelhut, I. C, W. Fiers and A. L Goldberg (1987). The toxic effects of tumor 
necrosis factor in vivo and their prevention by cyclooxygenase inhibitors. 
Proc. Natl. Acad. Sci. USA. 84: 4273-4277. 
Kinkhabwalla, M., P. Sehajpal, E. Skolnik, D. Smith, V. K. Sharma, H. Vlassara, A. 
Cerami and M. Suthanthiran (1990). 
A novel addition to the Τ cell repertory. 
J. Exp. Med. 171: 941-946. 
Kwiatkowski, D., A. V. S. Hill, I. Sambou, P. Twumasi, J. Castracene, К. R. Manogue, A. 
Cerami, D. R. Brewster and В. M. Greenwood (1990). 
TNF concentration in fatal, non-fatal cerebral, and uncomplicated Plasmodium fal­
ciparum malaria. 
Lancet 336: 1201-1204. 
Le, J. and J. Vilcek (1987). 
Biology of disease. Tumor necrosis factor and lnterleukin-1: cytokines with multiple 
overlapping biological activities. 
Lab. Invest. 56(3): 234-248. 
Piguet, P.-F., G. E. Grau and P. Vassalli (1990). 
Subcutaneous perfusion of tumor necrosis factor induces local proliferation of 
fibroblasts, capillaries, and epidermal cells, or massive tissue necrosis. 
Am. J. Pathol. 136(1): 103-110. 
Pohlman, T. H., K. A. Stannes, P. G. Beatty, H. D. Ochs and J. M. Harlan (1986). 
An endothelial cell surface factor(s) induced in vitro by lipopolysaccharide, 
interleukin-1, and tumor necrosis factor-α increases neutrophil adherence by a 
CDwl 8-dependent mechanism. 
J. Immunol. 136(12): 4548-4553. 
Polder, Т., С. Jerusalem and W. Eling (1983). 
Topographical distribution of cerebral lesions in mice infected with Plasmodium 
berghei. 
Tropenmed. Parasit. 34(4): 235-243. 
78 
Polder, T.W., W. M. С. Eling, J. H. A. J. Curfs, С. R. Jerusalem and M. Wyers-Rouw 
(1992). 
Ultrastructural changes in the blood-brain barrier of mice infected with Plasmodium 
berghei. 
Acta Leidensia 60: 31-46. 
Rubin, B. Y., S. L Anderson, S. A. Sullivan, B. D. Williamson, E. A. Carswell and L J. 
Old (1986). 
Nonhematopoietic cells selected for resistance to tumor necrosis factor produce tumor 
necrosis factor. 
J. Exp. Med. 164: 1350-1355. 
Schwarzer, E., F. Turrini, D. Ulliers, G. Giribaldi, H. Ginsburg and P. Arese (1992). 
Impairement of macrophage functions after ingestion of Plasmodium falciparum-
infected erythrocytes or isolated malarial pigment. 
J. Exp. Med. 176: 1033-1041. 
Shear, H. L, R. Srinivasan, T. Nolan and С Ng (1989). 
Role of IFN-γ in lethal and nonlethal malaria in susceptible and resistant murine 
hosts. 
J. Immunol. 143: 2038-2044. 
Stevenson, M. M., M. F. Tam and M. Nowotarski (1990). 
Role of interferon-g and tumor necrosis factor in host resistance to Plasmodium 
chabaudi AS. 
Immunol. Letters 25: 115-122. 
Sung, S.-S. J., J. M. Bjorndahl, С Y. Wang, H. T. Kao and S. Man Fu (1988). 
Production of tumor necrosis factor / cachectin by human Τ cell lines and peripheral 
blood Τ lymphocytes stimulated by phorbol myristate acetate and anti-CD3 antibody. 
J. Exp. Med. 1 67: 937-953. 
Tsujimoto, M., Y. K. Yip and J. Vilcek (1986). 
Interferon-g enhances expression of cellular receptors for tumor necrosis factor. 
J. Immunol. 136: 2441-2444. 
Van Rooijen, N. (1989). 
The liposome-mediated macrophage 'suicide' technique. 
J. Immunol. Meth. 124: 1-6. 
Van Rooijen, N. (1992). 
Liposome-mediated elimination of macrophages. 
Res. Immunol. 143: 215-219 
Van Rooijen, N. and E. Claassen (1988). 
"In vivo elimination of macrophages in spleen and liver, using liposome-encapsulated 
drugs: methods and applications." 
In: Liposomes as drug carriers: trends and progress, (éd. G. Gregoriadus), pp. 131-
143, John Wiley and Sons, New York. 
Van Rooijen, N.. N. Kors and G. Kraal (1989). 
79 
Macrophage subset repopulation in the spleen: differential kinetics after liposome 
mediated elimination. 
J. Leuc. Biol. 45: 97-104. 
Wallach, D., H. Holtmann, H. Engelmann and Y. J. Nophar (1988). 
Sensitisation and desensitisation to lethal effects of tumor necrosis factor and 11-1. 
J. Immunol. 140: 2994-2999. 
Warrell, D. Α., Μ. E. Molyneux, and P. F. Beales (1990). 
Severe and complicated malaria. 
Trans. R. Soc. Trop. Med. Hyg. 84 (Suppl. 2): 1-65. 
80 
CHAPTER 5 
RECOMBINANT INTERFERON-γ AND THE DEVELOPMENT OF 
PARASITEMIA AND CEREBRAL LESIONS IN 
PLASMODIUM BEKGHEAINFECTED MICE 
J. H. A. J. Curfs, P. H. van der Meide, A . Billiau , 
J. H. E. Th. Meuwissen and W. M. С Eling 
Experimental Parasitology, in press. 
81 
SUMMARY 
Mice infected with Plasmodium berghei K173 parasitized 
erythrocytes develop severe hypothermia followed by death as a 
consequence of murine cerebral malaria early in the second week 
after infection. 
A single intraperitoneal injection of 105 Units of IFN-γ given 
between day 4 and day 6 post infection results in a transient 
decrease of body temperature. No effect on parasitemia and 
cerebral malaria is obtained by this treatment. 
Daily injections of relatively low doses of IFN-γ delays the patency 
of the infection for 2 days. Furthermore the proliferation rate of 
the parasites is reduced and the development of cerebral malaria is 
also delayed for 2 days. The reduction of body temperature, as 
found in untreated infected mice, is absent. 
Administration of IFN-γ by means of a continuous delivery from 
intraperitoneally inserted osmotic pumps (1.2x104 Units of IFN-γ/ 
24 hrs) also delays patency and inhibits parasitemia. Body 
temperature decreases during infection but mice are protected 
against the development of cerebral malaria. In nude mice, this 
treatment inhibits parasitemia to the same extent. However 
reduction of body temperature was also prevented. 
High doses of IFN-γ delivered by osmotic pumps (2.5x104 or 10 s 
Units of IFN-y/24 hrs) appear to be lethally toxic in conventional 
as well as in nude mice, independently of infection. Cerebral 
malaria-like symptoms are found in these mice. 
Treatment of infected C57BI/6J mice with antibody to IFN-γ 4 days 
before and after infection as well as on the day of infection, 
enhances parasitemia but does not affect the development of 
cerebral malaria. Single injections of anti-IFN^-antibody 6 hours 
prior to infection or 7 days after infection have no effect. In 
CBA/Ca mice, treatment with anti-IFN^-antibody enhances 
parasitemia, furthermore protection against cerebral malaria was 
obtained in part of the mice. 
INTRODUCTION 
lnterferon-γ (IFN-γ), a cytokine produced by activated T-cells and 
natural killer cells, can protect mice against infection with 
various pathogens (Murray et al. 1988, Belosevic et al. 1989, 
82 
McCabe et al. 1984). In experimental malaria models IFN-γ 
treatment inhibits infection of the liver by sporozoites (Carlin et 
al. 1985, Ferreira et al. 1986, Maheshwari et al. 1990) as well as 
proliferation of the asexual blood stages (Clark et al. 1987a, Shear 
et al. 1989, Meding et al. 1990). Furthermore, IFN-γ enhances the 
effect of antimalarial chemotherapy (Kremsner et al. 1991). 
Mice infected with Plasmodium berghei K173 may develop cerebral 
malaria depending on the parasite-mouse strain combination (Curfs 
et al. 1989, Grau et al. 1986, Clark et al. 1990). In the second week 
after infection mice develop severe hypothermia followed by death. 
Histopathological analysis of the brain of such mice reveals 
extensive interaction between leucocytes and the endothelium and 
cerebral hemorrhages (Polder et al. 1992). Mice that survive this 
period do not become severely hypothermic and do not develop 
cerebral pathology but die in the third week after infection or later 
with high parasitemias, anemia and/or secondary infections. T-
cells, and according to the results of Grau et al. (1990) most 
probably Th-1 cells, play a key role in the pathogenesis of cerebral 
malaria in mice (Curfs et al. 1989, Grau étal. 1990). In line with 
this role for Th-1 cells is the observation that treatment with 
anti-IFN- γ anti-body prevented development of the cerebral 
syndrome (Grau et al. 1989a). 
Infection of mice with P. bergfte/'-parasitized erythrocytes leads to 
activation of T-cells, thereby enhancing IFN-γ production (Grau et 
al. 1990). IFN-γ is known to exert a priming effect on mono­
cytes/macrophages for the production of TNF (Gifford et al. 1987). 
IFN^-primed monocytes, activated by (plasmodial) antigens, 
readily produce increased amounts of TNF (Bate et al. 1989). TNF 
enhances the expression of surface adhesion molecules on 
endothelial cells (Bevilacqua et al. 1985), increasing adhesiveness 
for leucocytes. The attachment of lymphocytes, monocytes and 
parasitized erythrocytes (sequestration) to the endothelial cells 
found in cerebral malaria, may lead to vascular obstruction and to 
strongly enhanced local TNF production which, according to Grau 
et al. (1989b), may result in endothelial damage. 
The high TNF levels in mice with cerebral malaria (ANKA model, 
Grau et al. 1989b), the enhancement of cerebral malaria after 
treatment with TNF during infection (K173 model, Curfs et al. 
1990a), as well as the prevention of cerebral malaria in the ANKA 
model after inhibition of monocytopoiesis (Grau et al. 1988), after 
treatment with anti-TNF antibody (Grau et al. 1989b) or anti-IFN-y 
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antibody (Grau et al. 1989a), which diminished TNF levels, all 
support this assumption. 
The experiments described in this paper show that in the P. 
berghei K173 model of cerebral malaria treatment with IFN-γ 
inhibits parasitemia, and depending on the dose and route of 
administration, prevented cerebral malaria. Moreover, treatment 
with anti-IFN-γ antibody led to increased parasitemia but did not 
affect the development of cerebral malaria in C57BI/6J mice. In 
CBA/Ca mice, the strain Grau et al. used in their experiments, 
protection against cerebral malaria was obtained in part of the 
mice. Different levels of IFN-γ production of the two mouse strains 
might explain this phenomenon. 
MATERIALS AND METHODS 
Mice: C57BI/6J and C57BI/6J nu/nu mice were obtained from a 
local colony and housed in plastic cages under specific pathogen-
free conditions with food (Hope Farms) and water ad libitum. Nude 
mice were housed in cages with filter hoods. CBA/Ca/Ola/Hsd mice 
were obtained from Harlan Olac Ltd., Shaw's Farm, Blackthorne, 
Great Britain. 
Parasite: Plasmodium berghei К173 was maintained by weekly 
transfer of parasitized erythrocytes (PE) from infected to naive 
mice. Experimental mice were infected with 1000 PE. 
Parasitemia: thin blood films were made from tail blood and 
stained with May-Grunwald and Giemsa's solutions. 
Body temperature: body temperature was measured by a 
Technoterm digital thermometer (Thermotex, The Hague, The 
Netherlands) which was inserted in the rectum and read after 18 
seconds. 
Light microscopy of brains, lung, liver, spleen and kidney was 
performed using routine histological procedures. Histopathology 
was carried out post mortem to asses the presence of hemorrhages. 
Interferon-γ : recombinant rat-IFN-γ (CHO cells) was obtained from 
the TNO Health Institute, Rijswijk, The Netherlands. 
Anti-IFN-γ antibodies: Protein-Α purified monoclonal antibody DB1 
against mouse IFN-γ was obtained from TNO Health Institute, 
Rijswijk, The Netherlands. A second monoclonal antibody against 
mouse IFN-γ, F3 (ascites) was obtained from the Rega Institute, 
Leuven, Belgium. Ascites containing irrelevant antibody was used 
as a control. 
Θ4 
Osmotic pumps: Alzet mini-osmotic pumps, model 2002, were 
purchased from Alza, Palo Alto, California. These pumps were 
filled with IFN-γ solubilized in pyrogen-free isotonic saline, and 
implanted intraperitoneally one day before infection. 
RESULTS 
Effect of a single injection with IFN-γ 
Groups of 2 to 6 mice received a single intraperitoneal injection of 
IFN-γ (105 Units) on days 1, 4, 5, 6, 7, 8 or 9 after intraperitoneal 
infection with 103 parasitized erythrocytes. In each group body 
temperature was measured before and 4, 7 and 24 hours after IFN-γ 
injection. In all mice parasitemia was determined on days 7, 9, 11 
and 14 post infection. 
IFN-γ injection had no effect on normal body temperature (36.8 °C ± 
0.3, n=10) in uninfected mice (results not shown), but caused a 
temporary decrease in elevated body temperatures in infected mice 
(figurel). 
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Figure 1 
Effect of a single intraperitoneal injection of 10 5 Units of IFN-γ given on different 
days after infection on body temperature in C57BI/6J mice. Mice are infected intra­
peritoneally with 10 3 Plasmodium berghei parasitized erythrocytes. The dif-ference 
between the body temperature at the moment of injection of IFN-γ and 4 and 7 hours 
later are depicted in the figure. SEM is indicated as error bars. 
Maximum reduction was observed 4 hours after IFN-γ injection on 
all occasions, and the body temperature returned to the original 
value within 24 hours (results not shown), except on day 9 when 
mice exhibited a progressive decrease of their body temperature 
85 
until death occurred 7 hours after injection of IFN-γ. The strongest 
effect of IFN-γ treatment on the body temperature was observed on 
days 4, 5 and 6 after infection. On day 6 after infection and 
onwards, recovery to the original temperature was increasingly 
delayed. 
IFN-γ treatment, as given in this experiment, had no significant 
effect on parasitemia (results not shown), and all infected mice, 
whether treated with IFN-γ or not, died in the second week of 
infection with cerebral lesions as revealed by post-mortem 
histology. 
Effect of daily treatment with IFN-y 
Groups of 3 mice were given daily intraperitoneal injections of 
5x104 Units of IFN-γ starting on the day of infection. Control 
groups received either no injections or saline. On the day of 
infection IFN-γ or saline was injected 6 hours after the infection 
and in the other side of the peritoneal cavity. Mice were infected 
intraperitoneally with 103 parasitized erythrocytes. Body temp­
eratures were measured before the injection of IFN-γ. 
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Figure 2 
Effect of daily intraperitoneal injections of 5x104 Units of IFN-γ on parasitemia and 
body temperature of C57BI/6J mice infected intraperitoneally with 1 0 3 parasitized 
erythrocytes. Start of treatment on the day of infection (day 0). SEM is indicated as 
error bars. 
Figure 2a shows that daily treatment with IFN-γ delayed the 
patency of the infection for approximately 2 days and reduced the 
proliferation rate of the parasites. Death of infected mice treated 
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with IFN-γ occurred approximately 2 days later than in untreated 
controls and all mice exhibited cerebral lesions as revealed by 
post-mortem histology. Daily injections with saline did not alter 
the course of parasitemia nor the development of cerebral malaria 
in comparison with untreated infected mice. Fig. 2b shows that the 
rapid and progressive decrease of the body temperature observed in 
infected control mice did not occur in IFN-y-treated mice. Since 
body temperature was measured before injection of the daily dose 
of IFN-γ, the decrease of the body temperature following IFN-γ 
treatment as described in the previous section was not observed in 
this experiment. The results show that daily treatment with IFN-γ 
both delayed development of parasitemia and of cerebral malaria 
by approximately 2 days. 
Effect of continuous IFN-γ release from osmotic pumps 
Mini-osmotic pumps containing IFN-γ were implanted intra­
peritoneal^ one day before infection. These pumps delivered a 
calculated dose of 1.2x104 Units of IFN-γ per 24 hours for a period 
of 23 days. Mice were infected intravenously with 103 parasitized 
erythrocytes. 
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Figure 3 
Effect of continuously released IFN-γ on body temperature and parasitemia in 
C57BI/6J mice infected intravenously with 10 3 parasitized erythrocytes. Mini-
osmotic pumps containing IFN-γ were implanted intraperitoneally one day before 
infection and delivered a calculated dose of 1.2x104 Units of ΙΡΝ-γ/24 hrs for 23 
days. Control animals received pumps containing solvent only. SEM is indicated as 
error bars. 
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The effect of a continuous supply of IFN-γ on parasitemia and body 
temperature is depicted in figures 3a+b. As observed in mice given 
daily bolus injections of IFN-γ, continuous release of IFN-/ f r o m 
the osmotic pumps delayed the patency of the infection and reduced 
the proliferation rate of the parasites (Fig. 3a). Body temperature 
(Fig. 3b) dropped further than in mice that received daily injections 
of IFN-γ (compare figures 2b and 3b), but then stabilized. The most 
striking observation was that 4 out of the 5 IFN-y-treated m ' c e 
survived the second week after infection and did not develop 
cerebral malaria as confirmed by post-mortem histopathology. 
Infected mice with osmotic pumps containing saline all developed 
cerebral malaria. 
In a subsequent experiment the effect of IFN-γ delivered by 
osmotic pumps was tested in nude as compared to conventional 
mice. Continuous IFN-γ delivery ( 1 0 4 Units of ΙΡΝ-γ/24 hrs) 
inhibited parasitemia in nudes t o the same extent as in 
conventional mice (fig. 4a). The drop in body temperature during the 
second week of infection in conventional and I F N ^ - t r e a t e d 
conventional mice was not found in the nude mice (fig. 4b). 
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Figure 4 
Effect of continuously released IFN-y on body temperature and parasitemia in 
conventional A) and nude (•) C57BI/6J mice (Δ and • represent saline treated 
control mice). Mini-osmotic pumps were implanted intraperitoneal^ one day before 
infection. Mice were infected with 1 0 3 parasitized erythrocytes intravenously. 
Calculated dose: 104 Units of IFN-y/24 hrs. SEM is indicated as error bars. 
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Figure 5 
Histopathology of an uninfected intact mouse treated with 2.5x104 Units of IFN-y/24 
hrs delivered by a mini-osmotic pump. Death 5 days after start of treatment. A: brain, 
B: liver, C: lung and D: kidney. Notice hemorrhages in brain and kidney and the high 
number of leucocytes in liver and lung vessels. Goldner stain; magnification A+D 200 
x, B+C 400 x. 
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None of the nude mice (IFN-y-treated nor controls) died in the 
second week of infection or exhibited brain lesions post-mortem. 
Four of the 7 IFN-y-treated conventional mice did not develop the 
cerebral syndrome. Untreated conventional mice all developed 
cerebral malaria after infection, as expected. 
Doses of IFN-γ higher than 104 Units/day were found to be lethally 
toxic irrespective of infection. Specifically, uninfected mice died 
4-6 days after implantation of pumps delivering 2.5x104 or 105 
Units of IFN-Y/24 hrs. Similarly treated infected conventional mice 
died at the same time; infected nude mice died somewhat later, i.e. 
between day 7 and 14 (results not shown). None of the infected 
mice exhibited any parasitemia. 
In order to document the toxicity of high doses of IFN-γ, we 
implanted osmotic pumps releasing 2.5x104 Units of IFN-γ/24 hrs 
in two mice. One mouse was sacrificed 6 days after implantation 
of the pump, the second mouse died on the same day. Histo-
pathological analysis of the sacrificed animal revealed severe 
changes in several organs (figure 5). An increased number of 
leucocytes as well as leucocyte margination was observed in blood 
vessels of lungs, liver and brain. In addition, hemorrhages were 
found in these organs as well as in the kidneys. These changes were 
independent of whether the mice were infected or not. The results 
show that daily injection of a bolus of 10s Units of IFN-γ is not 
lethal, whereas even a lower total daily dose of 2.5x104 Units of 
IFN-γ administered by continuous release is lethally toxic. 
Effect of anti-IFN-γ antibody 
The effect of treatment of C57BI/6J mice with two different anti-
IFN^-antibody preparations on body temperature and on 
parasitemia is depicted in fig. 6a+b. Groups of mice received 
intraperitoneal injections of 5 mg DB1 or 0.1 ml F3 on days -4, 0 
and +4 relative to the day of infection. Control mice received 
injections of 0.1 ml ascites fluid containing an irrelevant antibody 
or were given no injections at all. An additional group of 5 mice 
was left untreated to establish the effect of repeated injections 
on parasitemia and the development of cerebral malaria (not 
enclosed in figure 6). Mice were infected intraperitoneal^ with 
103 parasitized erythrocytes. 
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All mice experienced a drop in body temperature (fig. 6a) during the 
second week of infection and died. All mice developed histo­
logically verified cerebral malaria. No significant difference in 
body temperature or mortality was found between antibody treated 
and control mice. 
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Figure 6 
Effect of treatment with anti-IFN-γ antibody on body temperature and parasitemia in 
C57BI/6J mice. Mice were infected with 10^ parasitized erythrocytes 
intrapentoneally. Anti-IFN-yantibody was injected intraperitoneal^ 4 days before 
and 4 days after as well as on the day of infection. F3: 0.1 ml/injection; DB1: 5 
mg/mjection and control ascites 0.1 ml/injection. SEM is indicated as error bars. 
However, treatment with anti-IFN-γ antibody did exert an effect on 
parasitemia (fig. 6b). On day 7 after infection parasitemia in the 
F3-treated group was significantly higher than in the ascites fluid 
control group (p=0.10, t-test). In DB 1-treated mice parasitemia 
was not significantly different from that in the ascites fluid 
controls (p=0.12, t-test). On day 9 after infection, mice treated 
with either DB1 or F3 had developed a higher parasitemia compared 
to the ascites controls (p=0.04 resp. p=0.003, t-test). On day 11, 
parasitemia of mice treated with F3 was still significantly higher 
compared to the ascites fluid controls (p=0.03, t-test) whereas 
from the DB1 treated mice only one animal was alive. Parasitemia 
of untreated controls did not differ from parasitemia of mice 
injected with ascites fluid containing irrelevant antibody (p=0.18 
on day 7, and p=0.21 on day 9, t-test; on day 11 all untreated 
controls had died). 
In experiments in which DB1 was injected in C57BI/6J mice either 
6 hours prior to infection (5 mg), or on day 7 after infection (1 
mg), or one day before and 4 days after infection (1 mg) no 
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protection against cerebral malaria was obtained. Furthermore, 
these treatments also failed to exert significant effects on 
parasitemia, drop in body temperature or mortality (results not 
shown). 
Anti-IFN-y-antibody injected intraperitoneally into CBA/Ca mice 
on days -4, 0 and +4 relative to infection with 103 parasitized 
erythrocytes, affected parasitemia as well as the development of 
cerebral malaria. Of 3 mice receiving injections of 0.1 ml F3 per 
mouse, 2 did not develop cerebral malaria. When 3 mice were 
injected with 5 mg DB1 each, one mouse did not develop cerebral 
malaria. Untreated control mice (n=9) all developed cerebral 
malaria. Parasitemia of antibody-treated mice was significantly 
enhanced only on the seventh day after infection (p=0.017 for F3 
treatment and p=0.003 for DB1 treatment, t-test) (results not 
shown). 
DISCUSSION 
In the experiments described in this paper treatment with IFN-γ of 
P. berghei K173-infected mice temporarily reduced body 
temperature, delayed patency, inhibited proliferation of the 
parasites and also prevented development of cerebral lesions, 
depending on the regimen used. Repeated injections and 
particularly continuous delivery of IFN-y inhibited parasitemia to a 
greater extent when the dose of IFN-γ per given time interval was 
increased. Only continuous delivery of IFN-γ was able to prevent 
development of cerebral malaria. 
The results also showed that the effect of continuous delivery of 
IFN-γ is much stronger than that of intermittent bolus injection. 
Daily injections of 105 Units of IFN-γ was not lethally toxic, but 
continuous release at a rate of 2.5x104 Units of IFN-y per 24 hours 
was lethal, independent of infection. The histopathological picture 
of mice dying of a lethal dose of IFN-γ resembles that seen after a 
lethal dose of TNF in mice (Grau et a/. 1987, Curfs et al. 1993), IL-
1 and TNF in rabbits (Ramilo et al. 1990), IFN-γ in rats (Steininger 
et al. 1988) and, with respect to white blood cell margination and 
development of hemorrhages in the brains even resembled the 
picture of cerebral malaria in P. berghei-'mfected mice (Polder et 
al. 1992). IFN-γ is known to enhance TNF-receptor expression 
(Aggarwal et al. 1985) on various celltypes and to cause enhanced 
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TNF production ¡η response to various inducers. Elevated TNF 
production and increased TNF sensitivity could provide an 
explanation for the histopathological phenomena found when high 
doses of IFN-γ are administered to mice. 
Transient hypothermia has been observed after TNF treatment in 
young rats (Kettelhut et al. 1987) as well as in P. berghei-infected 
mice (Curfs et al. 1990b). In addition, TNF treatment is also known 
to enhance development of cerebral malaria in mice (Curfs et al. 
1990a, 1993). Hypothermia after IFN-γ treatment may therefore be 
mediated by an IFN-γ-dependent release of TNF from a rapidly 
increasing number of activated monocytes/macrophages, although 
activation of certain types of lymphocytes may also contribute to 
an increase in TNF levels (Morin et al. 1991, Sung et al. 1988). 
Hypothermia was found to increase when more TNF is given, or 
when TNF is given later during infection (Curfs et al. 1990b), but 
IFN-γ treatment had its maximal hypothermic effect when single 
injections were given on day 4, 5 or 6 after infection. When IFN-γ 
was given later a delayed recovery to normal temperature was 
found. Moreover, single injections of IFN-γ did not accelerate the 
development of cerebral malaria as did TNF. Death on day 9 after 
infection 7 hours after IFN-γ treatment is not different from death 
of some untreated but infected controls dying with cerebral 
malaria on day 9 too. 
A dose-dependent inhibition of parasitemia by IFN-γ was also found 
by Clark et al. (1987a) in a non-lethal P. chabaudi adami infection 
in CBA/CaH mice, and by Shear et al. (1989) in a P. yoelli infection 
in mice. Shear found that the presence or absence of an inhibitory 
effect of IFN-γ treatment depends on the parasite-mouse strain 
combination. The delay of death by 2 days in infected mice treated 
daily with IFN-γ as observed in our experiments (compare figures 2 
and 4) was also present in the experiments of Shear et al. (1989) 
with susceptible, lethal P. yoellhmouse infections. Also Meding et 
al. (1990) found a slight delay in parasitemia after IFN-γ treatment 
of P. chabaudi cnabauoV-infected C57BI/6 mice. Clark et al. 
(1987a) even found a delay of patency of 5 days in P. chabaudi 
adam/'-infected CBA/CaH mice treated with IFN-γ. Furthermore, 
Kremsner et al. (1991) found that IFN-γ enhances the effect of 
antimalarial chemotherapy in P. vinckei-ìnfecteó Balb/c mice, 
ultimately leading to protection. 
As an interpretation of the data, Clark et al. (1987a) and Shear et 
al. (1989) suggested that a parasite-dependent IFN-
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γ response, being enhanced by exogenous IFN-γ, activates 
macrophages and enhances production of reactive oxygen molecules 
with antiparasitic activity, as well as the release of TNF. Also 
Kremsner et al. (1991) speculate on the stimulatory capacity of 
IFN-γ on monocyte/macrophage-activation. The antiparasitic effect 
of reactive oxygen molecules is well-established (Clark et al. 
1987a, Ockenhouse et al. 1984). Treatment of mice with butylated 
hydroxyanisole, a scavenger of reactive oxygen molecules, 
increases the development of parasitemia (Clark et al. 1987a). 
However, the decrease of the parasitemia after crisis appears to 
take place after the peak of reactive oxygen molecules (Shear et 
al. 1989). Treatment with TNF before or during the prepatent period 
has been reported to protect mice against infection with P. 
chabaudi (Clark et al. 1987a, Stevenson et al. 1990), whereas TNF 
treatment during a rising infection has been found to enhance its 
severity (Curfs et al. 1993, Grau et al. 1989b, Ockenhouse et al. 
1984). In our model, in accordance with the results obtained with 
IFN-γ treatment, we found that treatment of infected mice with 
anti-IFN-γ antibody caused increased proliferation of the parasite. 
This might be the result of a lowered production of reactive oxygen 
molecules as well as of a lowered production of TNF. Why this 
effect requires administration of antibody both before and during 
infection remains unclear. 
Although TNF can exert a protective effect against malaria, it is 
also considered to play an important role in bringing about the 
cerebral pathology in P. berghei ANKA-infected mice (Grau et al. 
1989b). The cerebral syndrome is associated, indeed, with high 
blood TNF levels. Furthermore anti-TNF-antibody treatment can 
prevent the complication (Grau et al. 1987) while TNF treatment 
can enhance the morbidity of the infection and development of a 
cerebral malaria-like syndrome (Curfs et al. 1990a, 1993, Clark 
et al. 1987b, Grau et al. 1987). An IFN-Y-dependent release of TNF 
might therefore cause aggravation of the infection, which we found 
indeed to be the case when IFN-γ was given late (day 8 after 
infection). On the other hand, a protective effect is found when 
IFN-γ is given early during infection. It is important to note that 
the major effect of IFN-γ treatment is found to consist of a delay 
of patency in the lethal Plasmodium-mouse strain combinations, 
and less so in an ongoing infection (Shear et al. 1989 and this 
manuscript). In line with this is the observation by Shear et al. 
(1989) that enhanced production of reactive oxygen molecules falls 
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back before peak parasitemia. 
Treatment with anti-IFN-γ antibody has been reported to prevent 
the development of the cerebral complication in P. berghei ANKA-
infected CBA/Ca mice (Grau et al. 1989a) when given before and 
during infection. It remains unclear why in our model with 
C57BI/6J mice this treatment failed to exert such an effect. One 
possible explanation might be that this strain of mice (C57BI/6J) 
is considered a high responder with regard to in vivo IFN-γ 
production in response to an antigenic stimulus, whereas the 
CBA/Ca strain is considered a low responder (Neta 1983). The 
difference in IFN-γ production between both strains can be as high 
as a factor 1000, depending on the antigen used for injection (Neta 
1983). The possibility that in the high responder C57BI/6J not all 
IFN-γ produced was neutralized by this treatment remains to be 
investigated. Our results in infected CBA/Ca mice treated with 
anti-IFN^-antibody further supports this explanation. 
The experiments described in this paper indicate that continuous 
release of IFN-γ prevents the development of cerebral malaria. 
This result is in line with the observation that IL-1 treatment can 
prevent development of cerebral malaria and suppress parasitemia 
in conventional but not in T-cell-deficient mice (Curfs et al. 
1990a) and that the IL-1 effect in conventional mice can be 
partiallly reversed by anti-IFN^-antibody treatment. 
How IFN-γ treatment prevents development of cerebral malaria 
remains to be established. An ongoing infection is associated with 
a strong increase in the number of monocytes/macrophages in the 
circulation and this is an important factor in the development of 
cerebral malaria (Curfs et al. 1990a). Probably these monocytes/ 
macrophages provide an endogenous pool of TNF, thereby increasing 
endothelial adhesiveness which leads to the accumulation of 
leucocytes in brain capillaries resulting in high local TNF 
production and endothelial damage. Continuous IFN-γ release in 
infected mice, either by IFN-γ treatment or by a parasite dependent 
continuous polyclonal T-cell response (Slade et al. 1989), may 
release TNF early and continuously, or may establish a refractory 
state in the monocytes/macrophages (Flick et al. 1985) thereby 
downregulating TNF release and preventing the development of 
cerebral malaria. If the first mechanism is operational it would 
explain the observations made by Stevenson et al. (Stevenson et 
al. 1990) who found that repeated injections of TNF from the start 
of the infection and onwards protected mice against a rapidly fatal 
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P. chabaudi infection. Refractoriness could lead to a lesser 
increase in TNF production, thereby slow down the development of 
cerebral malaria. 
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CHAPTER 6 
This chapter is devided into two sections (A and B), both 
describing the effect of the pro-inflammatory cytokine 
lnterleukin-1 on parasitemia and on cerebral malaria. Since results 
and discussion of both sections only partially overlap, it was 
decided to publish both sections separately in this thesis. 
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CHAPTER 6A 
LOW DOSAGES OF INTERLEUKIN-1 PROTECT MICE AGAINST LETHAL 
CEREBRAL MALARIA 
J. H. A. J. Curfs, J. W. M. van der Meer, R. W. Sauerwein 
and W. M. С Eling 
In: Journal of Experimental Medicine 172 (1990), 1287-1291. 
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SUMMARY 
In cerebral malaria pathological changes can be found in the brain 
of infected people and in the brain of P. berghei-'mfected mice. The 
pathogenesis of cerebral malaria in mice is believed to be due to 
an immunopathological reaction giving rise to an excessive 
production of cytokines such as IFN-γ and TNF. We find that low 
doses of IL-1 protect mice against cerebral malaria; IL-1 also 
inhibits parasitemia. The IL-1 effect on parasitemia was not 
observed in nude mice and was at least partly reversed in mice 
treated with IL-1 in combination with antibody to IFN-γ indicating 
the involvement of T-cells. Mice protected against development of 
cerebral malaria by IL-1 treatment developed the syndrome when 
TNF was given as observed in control infected mice or infected 
mice treated with inactivated IL-1. 
INTRODUCTION 
Cerebral malaria is an important cause of death in people infected 
with the human malaria parasite Plasmodium falciparum (Daroff 
et al. 1967). In a proportion of patients that die from cerebral 
malaria, inflammatory cells, loss of endothelial wall integrity and 
hemorrhages are found in the brain at autopsy (Maegraith 1948, 
Marsden et al. 1975). The pathogenesis of human cerebral malaria, 
including that of the hemorrhages, is largely unexplained. 
Similar findings are obtained in a murine malaria model after 
infection with Plasmodium berghei (Rest 1982, Curfs et al. 1989). 
Infection with this rodent malaria parasite can lead to the 
development of hemorrhages in the brains of hamsters (Wright et 
al. 1971), young rats (unpublished observations) and mice (Rest 
1982, Curfs et al. 1989, Wright et al. 1971). In P. berghei-infected 
mice the development of the hemorrhages coincides with a sudden 
and irreversible decrease of the body temperature followed by 
rapid death (Curfs et al. 1989). There are indications that a T-cell 
dependent immunopathological reaction and excessive production 
of cytokines, particularly lnterferon-γ (IFNy) and Tumor Necrosis 
Factor-α (TNF) play an important role in the pathogenesis of the 
brain hemorrhages in infected mice (Curfs et al. 1989, Grau et al. 
1988). Detrimental and even lethal effects of cytokines, such as 
TNF, have also been described in Gram negative bacterial 
infections and endotoxemias (Beutler et al. 1986). There are, 
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however, beneficial effects of cytokines too. The cytokine 
lnterleukin-1 (IL-1) administered in a low dose to mice, appears to 
protect mice from lethal infections due to bacteria such as 
Pseudomonas aeruginosa, Klebsiella pneumoniae, Listeria 
monocytogenes and fungi such as Candida albicans (van der Meer 
et al. 1988, van der Meer 1988, Ozaki et al. 1987, Czuprinsky et 
al. 1987, van 't Wout et al. 1988). Although the mechanism of 
protection has not yet been elucidated, it is an important question 
whether similar protection can be obtained against a parasitic 
disease such as lethal cerebral malaria. Therefore and because of 
the strong functional relationship between TNF and IL-1 (Le et al. 
1987) the effect of low dosages of human recombinant IL-Ια and 
IL-1 β was investigated in lethal Plasmodium berghe/'-infection in 
C57BI/6J mice. 
Low dose IL-1 treatment inhibited parasite proliferation in a dose 
dependent way, but only in intact mice, not in T-cell deficient nude 
mice. Independent of this effect on parasite proliferation IL-1 
treatment prevented development of cerebral malaria. 
Excessive TNF release is assumed to be responsible for most of the 
pathology associated with malaria (Clark et al. 1987a), and 
exogenous TNF given during infection can accelerate the 
development of the cerebral syndrome. IL-1 treatment, however, 
did not protect against this TNF accelerated development of 
cerebral malaria in P. berghei-mfected mice. 
MATERIALS AND METHODS 
Mice: C57BI/6J mice were obtained from a local colony and housed 
under specific pathogen free conditions with food (Hope Farms) and 
water ad libitum. 
Parasite: Plasmodium berg/7e/-K173 was maintained by weekly 
transfer of parasitized erythrocytes (PE) from infected to naive 
mice. Experimental mice were infected with 1000 PE 
intra peritoneally. 
Parasitemia: thin blood films were made from tail blood and 
stained with May-Griinwald and Giemsa's solutions. 
Body temperature: to measure body temperature the probe of a 
Tecnnoterm digital thermometer was inserted in the rectum and 
read after 18 seconds. 
Light and electron microscopy of brain tissue using routine 
histological procedures was carried out to detect the presence of 
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hemorrhages. 
Interleukin-Ί: human recombinant lnterleukin-la was obtained 
from Dr. P. Lomedico, Hoffmann LaRoche, Nutley. Human 
recombinant lnterleukin-1ß was obtained from Dr. Alan Shaw, 
Glaxo, Geneva. 
Recombinant Tumor Necrosis Factor-α was obtained from 
Boehringer-lngelheim FRG. 
Anti-lnterferon-γ antibody: monoclonal antibody (DB-1) against 
mouse IFN-y was obtained from Dr. P. H. van der Meide, T.N.О., 
Rijswijk, The Netherlands. 
RESULTS AND DISCUSSION 
Various IL-1 treatments were given to infected mice. When 80 ng 
of IL-1 α was given intraperitoneal^ for six consecutive days, 
starting on the day of infection, 78 % of the mice were protected 
against cerebral malaria and experienced only a limited and 
transient change in body temperature (Figure 1A), whereas all 
mice that received heat-inactivated IL-1 α (100°C for 20 min.) 
developed lethal cerebral malaria (Figure 1A, 2). In addition, a 
remarkable delay of the development of the parasitemia was 
observed in mice treated with IL-1 (Figure IB). Although at day 12 
parasitemia in IL-1 treated mice became as high as in control mice 
at day 7 (control mice were treated with inactivated IL-1), no 
dramatic decrease in body temperature and no cerebral 
hemorrhages occurred in the IL-1 treated group. 
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Figure 1 
Effect of IL-1 treatment on P. berghei -infection in C57BI/6J mice. 
Mice were infected with 1000 parasites i.v. From day 0 to 5 mice received 80 ng of 
IL-1 ( G ) or inactivated IL-1 (•) daily i.p. Summarized results from four 
independent experiments. Standard deviation of the mean is indicated as error bars. 
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Figure 2 
Light microscopy of the brain of a mouse treated with IL-1 (A+B), and of a control 
mouse treated with inactivated IL-1 (C+D). Notice the swollen bloodvessels, 
perivascular oedema (P) and the hemorrhage (H) in the cerebrum and cerebellum of a 
mouse treated with inactivated IL-1 (C+D) in contrast to the absence of 
histopathology in an IL-1 treated mouse (A+B). The IL-1 treated mouse was 
sacrificed on day 24 and the mouse treated with inactivated IL-1 was sacrificed on day 
9 after infection with 1000 parasitized erythrocytes. 
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Increasing daily dosages up to 320 ng IL-1 showed a further delay 
in the development of the parasitemia and again prevented 
development of cerebral malaria (Figure 3). 
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Figure 3 
Effect of increasing doses of IL-1 given from day 0 to 5 on parasitemia. C57BI/6J 
mice were infected with 1000 parasitized erythrocytes on day 0. 
It was found that a single intraperitoneal injection of 80 ng IL-1 α 
given three days after an intravenous infection with 1000 
parasites prevented death from cerebral bleedings in 50 % (n=10) 
of the animals. In addition, in all mice treated with IL-1 on day 3 
of infection, the course of the parasitemia was the same and 
independent of development of cerebral malaria. This makes it 
unlikely that protection against cerebral malaria by IL-1 
treatment is due to its effect on parasitemia. IL-1 given as a 
single injection at day 0 (n=5) or day 5 (n=5) did not have an effect 
on parasitemia and did not prevent cerebral malaria. Perhaps a 
more important observation was that IL-1 given shortly before the 
development of the cerebral syndrome i.e. on day 8 (n=10) neither 
affected the development of the syndrome. Comparable 
experiments using a six day treatment with IL-1 ß again showed 
protection against cerebral malaria and inhibition of parasitemia. 
Furthermore, implantation of osmotic pumps containing IL-1 α two 
days before infection (calculated dose 80 ng IL-1/24 hours; pumps 
active for 20 days) did have a similar effect on parasitemia and 
protected against the development of cerebral malaria as did the 
six day treatment where IL-1 was injected daily (n=5). Inhibition 
of the proliferation of the parasite and protection against cerebral 
malaria were seen as the main effects from the various IL-1 
treatments. 
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Based on these observations a series of experiments was 
performed in order to determine a possible mechanism of action of 
IL-1. First, it is known that parasite proliferation is strongly 
dependent on erythropoietic activity, probably related to the 
parasite's preference for reticulocytes (Hejna et al. 1974), and IL-
1 can suppress erythropoietin activity in vitro (Schooley et al. 
1987), though its effect in vivo is less clear (Schooley et al. 
1987). Therefore, it was investigated whether or not IL-1 
treatment suppresses erythropoiesis, thereby limiting 
parasitemia. Erythropoiesis was enhanced by letting 12 drops of 
blood from the retro-orbital plexus through a hematocrit capillary 
one day before IL-1 treatment. Three days after bleeding increased 
reticulocyte counts were obtained (untreated controls: 1.2 ±0.3%; 
n=5), but no difference was found between mice treated with IL-1 
(5.3 ±2.1 %; n=6) or inactivated IL-1 (5.3 ±3.3 %; n=3). Six days 
after bleeding reticulocyte counts had returned to normal values. 
Secondly, since mouse studies have shown that Τ lymphocytes 
play an essential role in the immunopathology of malaria (Curfs 
et al. 1989, van der Meer et al. 1988), we investigated whether IL-
1 could influence parasitemia in C57BI/6J nude mice (No cerebral 
malaria in T-cell deficient mice). Parasitemia was not influenced 
by IL-1 in these Τ cell-deficient animals (Figure 4). 
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Figure 4 
Effect of IL-1 treatment on P. berghei infection in C57BI/6J nude mice. Two days 
before infection with 1000 parasitized erythrocytes osmotic pumps (2002; Alza 
Corp., Palo Alto, CA) were implanted intraperitoneally containing either IL-1 (o ) or 
inactivated IL-1 ( • ) . Calculated IL-1 dosage, 80 ng IL-1/24 h. Pumps were 
operational for 20 d. Shown are summarized results of two independent experiments. 
SEM is indicated as error bars. 
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Thus, a direct effect on parasite proliferation is highly unlikely 
since IL-1 is not effective against parasitemia in nude mice. 
Apparently Τ lymphocytes or products of these cells are involved 
in this process, either by specific or non-specific immunological 
effects on the parasite. The fact that the action of IL-1 on the 
proliferation of the parasite is observed early during infection 
would be in favor of a non-specific effect on the parasite, e.g., via 
the release of lymphognes such as IFN-γ (Clark et al. 1987b). 
Indeed, when infected mice were treated with a combination of IL-
1 (80 ng/mouse/day for six days) and anti-IFN-γ antibody (1 
mg/mouse one day before and six days after infection) the 
suppressive effect of IL-1 on parasitemia was reversed: Eight days 
after infection parasitemia in IL-1 treated mice was 3.3 ± 3.2% 
(n=3) and in mice treated with IL-1 and antibody to IFN-y 7.3+ 0.9 
% (n=3) (p<0.06); parasitemia in untreated mice was still higher 
(15.7+4.1 %; n=3). IL-1 protection against the development of 
cerebral malaria, however, was not reversed when antibody to IFN-
γ was added to the treatment. Treatment of infected mice with 
antibody against IFN-γ without IL-1 had no effect on parasitemia 
(results not shown). These data support the hypothesis that IL-1 
dependent suppression of parasitemia is at least partly mediated 
by an IL-1 induced release of IFN-/ from T-cells. 
Specific immunological effects induced by IL-1 are not ruled out; 
IL-1 can lead to enhanced production of antibodies (Staruch et al. 
1983), which can contribute to the prevention of the cerebral 
syndrome. Timely treatment with IgG from malaria-immune mice 
prevents severe hypothermia as well as the development of 
hemorrhages under conditions, where there is no effect on the 
course of the parasitemia, indicating that specific antibodies can 
protect against cerebral malaria (Curfs et al. 1989). 
According to our data protection against cerebral malaria and 
delayed parasitemia are not linked. This is in agreement with 
experiments in lethal Gram negative infection; in these studies 
survival was not due to increased microbicidal mechanisms 
(Beutler et al. 1986, van der Meer et al. 1988). A hypothesis that 
came from those studies was that pretreatment with IL-1 
interfered with the lethal effects of cytokines such as TNF (van 
der Meer et al. 1988) e.g., by modulating the receptors for this 
latter cytokine or by another mechanism of desensitization 
(Wallach et al. 1988). A similar mechanism of protection could be 
operational here. The work of Grau et al. (1986) and Clark (1987) 
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suggests that TNF plays a pivotal role in the development of lethal 
malaria. Therefore it was investigated whether IL-1 would protect 
against the accelerated development of cerebral malaria of P. 
berghei-'mfected mice by injection of exogenous TNF. Mice were 
infected with 1000 parasites and were treated for five days with 
IL-1 or inactivated IL-1. On day 5 or later these mice were 
injected with 15 цд ree. human TNF (Boehringer, Ingelheim). Within 
a few hours after injection of TNF, both IL-1 treated mice as well 
as control mice became hypothermic and died with cerebral 
hemorrhages. Uninfected mice injected with the same dose of TNF 
did not exhibit a decrease in body temperature and did not die. 
These results argue against the possibility that protection 
against cerebral malaria induced by IL-1 is due to a decreased 
sensitivity to TNF. 
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CHAPTER 6B 
IL-1 TREATMENT INHIBITS PARASITEMIA AND 
PROTECTS AGAINST DEVELOPMENT OF CEREBRAL HEMORRHAGES 
IN P.BERGHEhWFECTED MICE 
J. H. A. J. Curfs, J. W. M. van der Meer, R. W. Sauerwein 
and W. M. С Eling 
In: The Physiological and Pathological Effects of Cytokines. Eds. С 
A. Dinarello, M. J. Kluger, M. С. Powanda and J. J. Oppenheim. Wiley-
Liss, New York 1990, pp. 331-337 
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INTRODUCTION 
Cerebral malaria is a life threatening disease complication and a 
considerable amount of people that die from this syndrome exhibit 
cerebral hemorrhages in their brain (Jerusalem et al. 1984). 
Plasmodium berghei infection in C57BI/6J mice is a suitable model 
to study cerebral malaria. Almost all C57BI/6J mice infected with 
P.berghei exhibit a sudden and dramatic decrease in body 
temperature, which coincides with the development of cerebral 
hemorrhages and death early in the second week after infection. 
Previous work showed that the spleen as well as T-cells play an 
important role in the development of hemorrhages (Curfs et al. 
1989). Others have shown that cytokines and particularly Tumor 
Necrosis Factor (TNF-a) and Interferon-gamma (IFN-γ) are crucial 
(Grau et al. 1988). 
Since TNF and IL-1 are related cytokines and IL-1 treatment 
appeared to protect against lethal bacterial and fungal infections 
(van der Meer 1988), we investigated the effect of IL-1 and TNF 
treatment on P. berghei infection in C57BI/6J mice. 
MATERIALS AND METHODS 
Mice: C57BI/6J mice were obtained from a local colony and housed 
under specific pathogen free conditions with food (Hope Farms) and 
water ad libitum. 
Parasite: Plasmodium berghei-КМЪ was maintained by weekly 
transfer of parasitized erythrocytes (PE) from infected to naive 
mice. Experimental mice were infected with 1000 PE 
intraperitoneal^. 
Parasitemia: thin blood films were made from tail blood and 
stained with May-Grünwald and Giemsa's solutions. 
Body temperature: To measure body temperature the probe of a 
Technoterm digital thermometer was inserted in the rectum and 
read after 18 seconds. 
Light microscopy: post mortem histology of brain tissue using 
routine histological procedures was carried out to detect the 
presence of hemorrhages. 
lnterleukin-1: human recombinant lnterleukin-ΐα was obtained 
from Dr. P. Lomedico, Hoffmann LaRoche, Nutley. Mini-osmotic 
pumps (Alzet model 2002, Alza, Palo Alto) were filled with IL-1 in 
order to deliver a calculated amount of 80 ng of either active or 
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inactivated (20 min., 100°C) IL-1 per 24 hours. These pumps were 
inserted intraperitoneal^ one day before infection and had an 
expected delivery period of 20 days. 
Recombinant Tumor Necrosis Factor-α (TNF) was obtained from 
Boehringer-lngelheim FRG. 
RESULTS 
Parasitemia, body temperature and death were scored in P.berghel· 
infected mice treated with either active or heat-inactivated IL-1, 
and brains were analysed for the presence of hemorrhages post 
mortem. Changes in body temperature and parasitemia in treated 
and control animals are depicted in Figure 1. 
Control mice treated with inactivated IL-1 all developed 
increasing parasitemia and a dramatic and irreversible decrease of 
body temperature shortly before they died early in the second week 
after infection. Histopathological analysis showed that all had 
developed cerebral hemorrhages. These findings are very similar to 
those observed in untreated mice infected with P. berghei (Curfs 
et al. 1989). 
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Figure 1 
Body temperature and parasitemia in infected mice treated with IL-1 ( o ) or 
inactivated IL-1 (•) delivered from osmotic pumps. 
Mice treated with active IL-1 did not exhibit a fatal collapse of the 
control of their body temperature, but only showed a limited and 
transient reduction in body temperature. Their parasitemia was 
considerably delayed and histopathological analysis post-mortem 
confirmed that none of the mice had brain hemorrhages. 
The effect of IL-1 treatment on parasitemia is impressive. In the 
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first week after infection IL-1 treatment results in an almost 
complete inhibition of parasite proliferation in comparison to 
controls. In the second week after infection parasitemia increases 
rapidly. 
Since others have shown that TNF plays an important role in the 
development of cerebral malaria in P. berghennfected mice (Grau 
et al. 1988) we investigated the effect of IL-1 treatment on the 
induction of cerebral malaria by TNF. Uninfected control mice 
appear not to be affected by treatment with as much as 250 цд of 
TNF. Infected mice become more sensitive to treatment with TNF in 
the course of infection. Thus, treatment with 15 цд hrTNF on day 5 
of infection resulted in a drop of body temperature of 2.5°C over a 
period of approximately 4 hours. The same treatment given on day 6 
caused a transient decrease of the body temperature of 4.3°C in one 
mouse and a progressive decrease in body temperature and death 
after 24 hours in another. Treatment with 15 μg TNF on day 8 
caused a rapid decrease in body temperature and death within 4 
hours. Histopathological analysis revealed that all TNF treated 
mice that died within 24 hours after treatment exhibited 
hemorrhages in their brains. 
Subsequently, mice protected against the development of cerebral 
malaria by IL-1 treatment were treated with 15 цд of TNF on day 8 
of infection. These mice developed a progressive decrease in body 
temperature until death and hemorrhages in their brain. Thus IL-1 
protection against cerebral malaria does not protect against the 
cerebral syndrome enhanced by TNF injection. 
DISCUSSION 
Treatment with low dose IL-1 inhibits parasite proliferation and 
protects against cerebral malaria in P. bergftez-infected mice. 
Previous experiments have shown that protection against cerebral 
malaria by IL-1 treatment was independent of the effect of IL-1 on 
proliferation of the parasite. Thus, a single injection of 80 ng of 
IL-1 on day 3 after infection protected 40 % of the mice against 
cerebral malaria but had no effect on parasitemia (Curfs et al. 
1990). Previous experiments also showed that multiple injections 
of 80 ng of IL-1 as well as higher doses of IL-1 progressively 
inhibited parasitemia when given early during infection. The 
results described here support this. It should be noted that 
inhibition of parasite proliferation by IL-1 is seen early after 
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infection, but is lost later on. Therefore, IL-1 dependent inhibition 
of parasite proliferation is independent of specific, anti parasitic 
immune reactions, which occur not until 6-7 days after infection. 
There are a number of possible explanations for the effect of IL-1 
on parasite proliferation and prevention of cerebral malaria (Figure 
2). 
The effect on parasite proliferation could be explained if IL-1 
treatment would inhibit erythropoiesis (an effect not described for 
IL-1); alternatively IL-1 could enhance natural killer cell 
production (Dempsey et al. 1982) which would inhibit parasitemia. 
Furthermore, IL-1 releases TNF and IFN-γ (Le et al. 1987), and 
these cytokines in turn may affect either erythropoiesis (Miller et 
al. 1989), or the parasite directly (Clark et al. 1987). The 
observation that an IL-1 dependent inhibition of parasite 
proliferation was not observed in T-cell deficient nude mice (Curfs 
et al. 1990) supports the possibility that the effect of IL-1 is 
mediated by IFN-γ. 
ACTH -»-cort icosteroids^lFN -^-TNF 
suppression of parasitemia 
activation T-cells ·+ I L - 1 • adjuvants-»• specific antibody 
proliferation NK-cells / 
/ prevention of cerebral malaria 
suppression erythropoiesis 
Figure 2. 
Schematic representation of possible mechanisms through which IL-1 could affect 
parasitemia and cerebral malaria. 
The mechanism by which IL-1 treatment protects mice against 
cerebral malaria remains unknown. The same holds for protection 
of mice against a lethal bacterial and fungal infection (van der 
Meer 1988). We have shown that IL-1 treatment is most effective 
when given from the day of infection for a period of 6 days i.e. 4-5 
days before the cerebral syndrome develops (Curfs et al. 1990). 
Elsewhere we hypothesized (van der Meer 1988) that IL-1 
treatment might interfere with the lethal effects of TNF (Holtmann 
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et al. 1987), or a mechanism of desensitization (Wallach et al. 
1988). The experiments described here argue against this option, 
since IL-1 treatment does not protect against accelerated 
development of cerebral hemorrhages induced by injection of TNF 
during infection. 
Another possibility is that an IL-1 dependent release of ACTH and 
corticosterone supresses production of mRNA for TNF (Beutler et 
al. 1986). The possibility to prevent cerebral malaria in mice by 
timely treatment with corticoids has been described before (Curfs 
et al. 1989). Corticosterone levels generated during low dose IL-1 
treatment in infected mice, however, have not yet been determined. 
It has been reported that IL-1 has adjuvant properties (Staruch et 
al. 1983). It has also been shown that passive transfer of 
antibodies from immune mice protects against the development of 
cerebral malaria. In addition, it was found that pre-immunisation 
with parasites one week before challenge infection, as well as 
infection with a high dose of parasites ( ΙΟ 8 PE in stead of ΙΟ3 PE) 
protects against development of cerebral malaria (Curfs et al. 
1992). These results support the idea that the presence of specific 
antibodies can protect against development of the cerebral 
syndrome. IL-1 treatment early during infection might stimulate a 
specific antibody response and thereby protect against the 
syndrome. 
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CHAPTER 7 
IL-1 RECEPTOR ANTAGONIST SUPPRESSES PARASITEMIA, BLOCKS 
THE EFFECT OF IL-1 AND PREVENTS CEREBRAL MALARIA IN 
PLASMODIUM BERGHEhMfECJED MICE. 
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INTRODUCTION 
The pro-inflammatory cytokine interleukin-1 (IL-1) is thought to 
play a role in various diseases. It induces fever, neutrophilia, 
hypoferremia, hypotension, endothelial cell activation, lactic 
acidosis, vascular leakage, increased expression of adhesion 
molecules, pulmonary congestion and many other responses, and 
can even contribute to shock and death (Dinarello 1991, Smith et 
al. 1990). On the other hand, IL-1 treatment can protect against 
several types of lethal bacterial infections (van der Meer 1988, 
van der Meer et al. 1988, Czuprinsky and Brown 1987, Ozaki et al. 
1987) and cerebral malaria (Curfs et al. 1990a). Protection might 
depend on the immunomodulating activities of IL-1, such as 
downregulation of cytokine receptors (Holtmann and Wallach 1987, 
Matsushima et al. 1986, Ye et al. 1991), activation of Τ- and Β-
cells, enhancement of IL-2 receptor expression and synthesis, 
natural killer (NK) cell activity and lymphokine gene expression 
(Dinarello 1991). 
The description of two types of IL-1 receptors (IL-IRti and IL-
I R t u ) (Chizzonite et al. 1989) and the availability of recombinant 
IL-1 receptor antagonist (IL-1 RA) (Hannum et al. 1990) makes it 
possible to further analyse the role of IL-1 in pathology or 
protection. 
I L - I R t i is found on T-cells, endothelial cells and on human 
monocytes. IL-1 R t i l i s found on B-cells, neutrophils, bone marrow 
cells and murine macrophages (Dinarello 1991). Human IL-1 RA 
binds to both types of IL-1 receptors on human cells, whereas on 
murine cells it only binds to the IL-IRti and not to the IL-1 R t n 
(Carter et al. 1990, Dinarello et al. 1991). This differential effect 
of IL-1 RA on IL-1 receptors of murine cells allowed us to further 
define the protective effect of IL-1 in murine malaria infection. 
IL-1-treatment of C57BI/6J mice infected with Plasmodium 
berg/7e/-K173 suppressed parasitemia in a dose-dependent way 
(Curfs et al. 1990a), and independent of the effect on parasitemia 
also prevented the development of cerebral malaria (Curfs et al. 
1990a,b). Administration of IL-1 RA to infected mice also 
suppressed parasitemia (although to a lesser extend than IL-1 did) 
and prevented cerebral malaria. In addition, IL-1 RA blocked at 
least part of the effect of IL-1 on parasitemia. 
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MATERIALS AND METHODS 
Mice: female C57BI/6J mice, approximately 8 weeks of age, were 
obtained from a local colony and housed in plastic cages under 
specific pathogen-free conditions with food (Hope Farms) and 
water ad libitum. 
Parasite: the murine malaria parasite Plasmodium berg/7e/-K173 
was maintained by weekly transfer of parasitized erythrocytes 
(PE) from infected to naive C57BI/6J mice. Experimental mice 
were infected with 1000 PE intraperitoneal^. 
Parasitemia: Thin blood films were made from tailblood and 
stained with May-Grünwald and Giemsa's solutions. Parasitemia 
was determined by counting the number of infected erythrocytes 
vs. the total number of erythrocytes. 
Body temperature: body temperature was measured by a 
Technoterm digital thermometer (Thermotex, The Hague, The 
Netherlands) which was inserted in the rectum and read after 18 
seconds. 
Cerebral malaria: the majority of C57BI/6J mice infected with 103 
parasitized erythrocytes develop severe hypothermia followed by 
death early in the second week after infection. As described before 
(Curfs et al. 1989), there is a close correlation between hypo-
thermia, followed by death in the second week after infection, and 
presence of cerebral lesions, particularly hemorrhages. Mice that 
survive this critical phase die in the third week after infection or 
later. These mice experience only a limited and transient 
hypothermia and do not exhibit cerebral lesions. The course of the 
parasitemia's of mice with or without cerebral malaria is similar. 
Histology: after removal, brain tissue was fixed for four hours in 
Carnoy's fluid. Using routine histological procedures, 5 цт paraffin 
sections were stained with PAS-Haematoxylin or Goldner's 
trichrome stain. 
lnterleukin-1: human recombinant Interleukin-la (IL-1 ) was 
obtained from Dr. P. Lomedico, Hoffmann LaRoche, Nutley. Mice 
were injected intraperitoneally with 80 ng IL-1 in 0.2 ml pyrogen-
free saline for six consecutive days, starting on the day of 
infection. 
lnterleukin-1 receptor antagonist: human lnterleukin-1 receptor 
antagonist (IL-1 RA; 30 mg IL-1 RA/ml in a solution containing 10 
mM Na3P04, 0.1 mM EDTA and 150 mM NaCI, pH 7.0) was a kind gift 
from Dr. R. С Thompson, Synergen, Boulder, USA. Further dilutions 
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were made in pyrogen-free saline. 
Osmotic pumps: Alzet mini-osmotic pumps, model 2001, were 
purchased from Alza, Palo Alto, California. These pumps were 
filled with IL-IRA m order to deliver a calculated amount of 34 цд 
IL-1 RA per 24 hours. The pumps were inserted intraperitoneally 
and had an expected delivery period of 8.5 days. 
RESULTS 
In a first experiment we determined the effect of IL-1RA on P. 
berghei infection in mice (Figure 1). One group of mice (n=3) was 
injected with 40 цд of IL-1RA intraperitoneally every 6 hours on 
the fifth and sixth day after infection (2 mg/kg body weight per 
injection). A second group of mice (n=3) was treated with IL-1RA 
delivered by intraperitoneally inserted osmotic pumps. The pumps 
were implanted on the day of infection and delivered a calculated 
amount of 34 цд of IL-1 ra per hour for a period of 8.5 days. A third 
group of mice (n=3) was treated with saline (controls). All mice 
were infected with 103 parasitized erythrocytes intravenously. 
Parasitemia and body temperature were recorded from day 7 after 
infection and onwards. 
11 12 13 14 IS 
Days after infection 
12 13 14 15 
DayB after infection 
Figure 1. 
Body temperature and parasitemia in infected mice treated with IL-1 RA on day 5+6 
(•, n=3), treated with IL-1 RA delivered by osmotic pumps (Δ, n=3) or treated with 
saline ( · ) . 
All mice developed severe hypothermia and died in the second week 
after infection. Hypothermia and death in mice treated with IL-1 RA 
on day 5 and 6 after infection was delayed (Figure 1 a). 
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Parasitemia was found to be inhibited by injection of IL-1RA up to 
day 11 after infection; IL-1RA delivered by osmotic pumps delayed 
parasitemia up to day 10. Eventually, parasitemia reached values 
as high as in saline treated controls (Figure lb). 
Since IL-1 is known to inhibit parasitemia and to protect against 
cerebral malaria (Curfs et al. 1990) we determined the effect of 
IL-1 RA on the action of IL-1. Therefore we treated individual 
groups of mice (n=3) with either IL-1 RA or IL-1 alone, or with both 
IL-1 RA and IL-1; control animals (n=3) were treated with saline. 
IL-1 was injected intraperitoneally at a dose of 80 ng/mouse for 
the first six days of the infection, and IL-1 RA was injected 
intraperitoneally at a dose of 40 mg/12 hours also during the first 
six days of the infection (in mice receiving both IL-1 and IL-1 RA 
the injection of the substances was carried out several hours apart 
and at different locations). All mice were infected with 10 3 
parasitized erythrocytes intraperitoneally. 
Body temperature of mice treated with both IL-1 and IL-1 RA or 
with IL-1 RA alone decreased to approximately 30°C , but then 
stabilized (Figure 2a) and was not followed by death as observed in 
the controls. Body temperature of infected mice treated with IL-1 
alone decreased to a lesser extent. Fourteen days after infection 
all surviving mice were sacrificed and prepared for histological 
examination. No cerebral lesions were found in the brains of IL-1 
and/or IL-1 RA treated mice except for one mouse treated with IL-
1 & IL-1 RA and dying 10 days after infection, whereas all saline 
treated mice (dying on day 10, 11 and 11 after infection) exhibited 
cerebral hemorrhages upon post mortem histological analysis. 
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Figure 2. 
Body temperature and parasitemia in infected mice treated with IL-1 alone (| 
IL-1 RA alone (Q, n=3), IL-1 and IL-1 RA (A, n=3) or saline ( · , n=3). 
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n=3), 
Parasitemia of mice treated with IL-1 alone was inhibited as 
described before (Curfs et al. 1990), whereas parasitemia of mice 
treated with both IL-1 and/or IL-1 RA was higher than in the IL-1 
treated mice but still lower compared to the controls (Figure 1 b). 
DISCUSSION 
The development of cerebral malaria (CM) in mice is associated 
with an increased production of cytokines, particularly TNF and 
IFN-γ (Clark 1987, Grau et al. 1988). IL-1 treatment prevents the 
cerebral syndrome possibly by interference with the accompanying 
cytokinemia or by causing desensitization (Holtmann et al. 1987, 
Wallach et al. 1988); other explanations are possible as well 
(Curfs et al. 1990a,b). Treatment with IL-1 RA also prevents the 
cerebral syndrome (i.e. only a limited decrease of the body 
temperature and absence of petecchiae in the brain is seen) 
suggesting that endogenous IL-1 is involved in the development of 
this syndrome. Since IL-1 RA only reacts with mouse IL-lRti 
(expressed on T-cells and endothelial cells) and not with mouse IL-
1 R t n (expressed on B-cells and monocytes), endogenous IL-1 
probably contributes to the development of CM by its effect on T-
cells or endothelial cells. 
IL-1 treatment suppresses parasitemia, which is at least partly 
mediated by IFN-γ production of T-cells (Curfs et al. 1990a). 
Treatment with IL-1 RA also suppresses parasitemia, though less 
effectively. This suggests that endogenous IL-1 is also involved in 
the proliferation of the parasite. Since treatment with both IL-1 
and IL-1 RA suppresses parasitemia to the same extend as IL-1 RA 
alone, it is likely to assume that the suppressive effect of IL-1 
might be completely blocked and that the observed suppressive 
effect when both substances are given is comparable to the effect 
of IL-1 RA alone. 
The results obtained by IL-1 and IL-1 RA treatment are compatible 
if it is assumed that IL-1 treatment causes downregulation of IL-
I R t i and IL-1Rtn expression. Treatment with rH-IL-1RA only 
inhibits the IL-1 Rti-dependent part of endogenous IL-1 
stimulation and this might explain why the parasitemia and the 
body temperature in IL-1RA-treated mice lies between that of the 
IL-1-treated and control infected mice. 
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CHAPTER 8 
GENERAL DISCUSSION 
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The aim of this study was to elucidate factors contributing to the 
pathogenesis of cerebral malaria. Therefore we investigated an 
experimental model in which mice develop a cerebral syndrome 
after inoculation of Plasmodium berghei-infected erythrocytes. 
Earlier studies conducted in our laboratory (Polder 1988 thesis) 
indicated that histopathological changes observed in murine 
cerebral malaria resemble those observed in human cerebral 
malaria. These studies supported the immunological theorie which 
implicates that immunopathological reactions are involved in the 
pathogenesis of cerebral malaria. 
The role of the spleen and particularly T-cells is established in 
experiments described in chapter 2. Spleen-/T-cell-dependent 
reactions are involved in the development of cerebral lesions in 
infected mice. These data confirmed and extended the role of T-
cells (i.e. CD4+-cells) in the pathogenesis of murine cerebral 
malaria described by others in an analogous model (Grau et al. 
1986). 
A timely treatment with dexamethasone prevents cerebral malaria. 
This may be explained by its well known immunosuppressive 
properties. On the other hand, dexamethasone also inhibits TNF 
production by monocytes/macrophages, and this cytokine is also 
implicated in the development of cerebral malaria. Both in patients 
and in mice developing cerebral malaria serum-TNF levels are 
enhanced (Scuderi et al. 1986, Kern et al. 1988, Grau et al. 1987) 
and injection of low amounts of TNF into infected mice induces 
cerebral malaria-like pathology (Clark et al. 1987, 1990, chapter 
4). In addition, in mice with cerebral malaria monocytes are found 
in close relation to the endothelium and since monocytes are an im­
portant source of TNF, inhibition of TNF synthesis might very well 
results in protection against cerebral malaria. Inhibition of 
cerebral malaria in mice is obtained when dexamethasone is given 
before day 5 after infection only and this might explain why 
administration of dexamethasone to patients that already developed 
cerebral malaria does not improve and even aggravates the clinical 
condition (Warrel et al. 1982, Hoffman et al. 1988). 
The enhanced production of TNF during cerebral malaria probably 
does not only result from an increased number of monocytes alone. 
TNF production by monocytes/macrophages might be enhanced by 
increased levels of IFN-γ produced during infection by activated T-
cells (Gifford et al. 1987, Shear et al. 1989). Since IFN-/ enhances 
TNF receptor expression this may further enhance sensitivity for 
132 
TNF (Aggarwal et al. 1985, Tsujimoto et al. 1986). Indeed, 
treatment of mice with anti IFN-y-antibody prevents the 
development of cerebral malaria (Grau et al. 1989). Remarkably, 
continuous treatment of mice with IFN-γ during infection also 
prevents the development of cerebral hemorrhages (Chapter 5). This 
may depend on the induction of a refractory state in monocytes 
(Flick et al. 1985) thereby downregulating TNF release, or on an 
early and continuous release of TNF resulting in decreased TNF 
sensitivity by down-regulation of TNF receptor-expression or 
desensitisation (Wallach et al. 1988). 
As indicated before, monocytes are an important source of TNF and 
during malaria infection monocytopoiesis is enhanced. Suppression 
of monocytopoiesis by treatment of infected mice with antibodies 
to IL-3 and GM-CSF prevented the development of cerebral malaria 
(Grau et al. 1988). This suppression was explained by the inhibition 
of TNF production. On the other hand, suppression of 
monocytopoiesis before or early during infection may also prevent 
the induction of (an) immuno-pathological reaction(s) due to 
absence of antigen presentation by monocytes to T-cells. 
Elimination of macrophages by treatment with liposomal 
dichloromethylene diphosphonate (lip-CI2MDP) prevented cerebral 
malaria, but only when given before day 5 of infection. On the one 
hand this result supports a role for macrophages and TNF in the 
pathogenesis of cerebral malaria, but leaves to be explained why 
treatment at later stages is ineffective. It may also indicate that 
after day 5 of infection TNF is also substantially produced by other 
cells that are not eliminated by lip-CI2MDP treatment (chapter 5). 
TNF can also be produced by other hematopoietic cells (Kinkhabwala 
et al. 1990, Sun-Sang et al. 1988, Rubin et al. 1986) and apart from 
monocytes lymphocytes are also found to adhere to the endothelium 
during experimental cerebal malaria (Polder 1988 thesis). 
Suppression of antigen presentation by lip-CI2MDP treatment, 
which later during infection has become irrelevant for the further 
evolution of the cerebral syndrome may be another explanation. 
Finally, the observed inability of macrophages containing malaria 
pigment to phagocytose additional material (e.g. Iip-CI2MDP) (Schwarzer et al. 1992) making them insensitive to elimination by 
this treatment and leaving a large pool of TNF producing cells may 
also explain the observation. 
Since immunereactivity seems to lead to cerebral pathology and 
because mice can be protected against cerebral malaria by treat-
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ment with malaria-immune mouse IgG (Curfs et al. 1989), we 
assumed that immunization against cerebral malaria as described 
in chapter 3 protects mice by inducing an antibody response 
directed against antigen(s) that trigger the immunopathological 
reaction(s). Possible candidates for antigens that induce 
immunopathological reactions are exoantigens (chapter 3). Malarial 
exoantigens have proven to induce TNF in vitro as well as in vivo 
(Bate et al. 1989). Furthermore, immunization with these antigens 
prior to infection protects mice against the development of 
cerebral malaria. Successful immunization against cerebral malaria 
either using large numbers of killed parasites, live parasites for a 
period of two days, or a high-dose infection might all depend on 
the same effect, i.e. in vivo production and release of exoantigens 
may generate a protective antibody response. 
In addition to protection against bacterial and fungal infections, 
the early treatment with the cytokine IL-1 also protected against 
cerebral malaria and inhibited parasite proliferation in a dose 
dependent manner (chapter 6). This effect may depend on the well 
established adjuvant effects of IL-1. Treatment of mice with IL-1 
may result in an early generation of specific antibody (e. g. against 
exoantigens). Apart from this effect, protection against cerebral 
malaria by treatment with IL-1 may also depend on the induction of 
IFN-γ. A further possibility is that IL-1 increases ACTH production 
resulting in elevated levels of corticosteroids that can inhibit the 
production of TNF. Remarkably, treatment of mice with IL-1 
receptor antagonist also protects mice against cerebral malaria. 
Apparently endogenous IL-1 production is involved in the patho­
genesis of cerebral malaria. However, in contrast to TNF, injection 
of relatively high doses of IL-1 later during infection did not result 
in accelerated development of the cerebral syndrome. This is 
surprising in view of the considerable overlap in function between 
TNF and IL-1 (Le et al. 1987) and their synergistic action in shock 
models (Dinarello 1989, Okusawa et al. 1988). Interestingly, the IL-
1 RA only binds to mouse IL-1 Rti which is expressed on T-cells and 
endothelial cells whereas it does not bind to IL-1 R t n expressed on 
B-cells and monocytes. This may indicate that the effect of 
endogenous IL-1 on T-cells is important in the development of 
murine cerebral malaria. 
These results prompted the hypothesis that cerebral malaria is the 
endresult of (a) deleterious CD4+-cell mediated immunological 
reaction(s) initiated in the host in response to parasitic antigen(s). 
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These reactions lead to a cytokinemia predominantly involving IFN-
v (priming of monocytes for production of TNF), IL-1 (stimulatory 
effect on T-cells) and TNFa (effects on endothelium). The 
interrelations between these cytokines and their involvement in the 
pathogenesis of cerebral malaria is depicted in figure 1. 
Figure 1 
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Chapter 1 
The introduction provides an overview on human malaria and the 
malaria problem with special emphasis on cerebral malaria. The 
various theories on the pathogenesis of cerebral malaria are 
described as well as various experimental models. The 
experimental model of Plasmodium berghei malaria in mice is 
described in more detail and the aim of this study is stated. 
Chapter 2 
In this chapter immunological characteristics of the P. berghei 
model are discussed. Cerebral malaria in mice developed in the 
second week after infection and was characterized by a rapidly 
progressive hypothermia (body temperature decreases below 30°C), 
the development of petecchial hemorrhages and perivascular edema 
followed by death the second week of infection. The development of 
cerebral malaria in mice was spleen-dependent and could be 
prevented by irradiation of the spleen, treatment with dexa-
methasone, anti-T-cell serum or malaria-immune mouse serum. 
Chapter 3 
Since murine cerebral malaria is characterized by the induction of 
immunopathological reactions it may be possible to immunize 
against this severe complication. Increasing the number of 
parasites in the infectious inoculum, injection of large numbers of 
disrupted parasitized erythrocytes, a two day immunizing infection 
as well as injection with plasmodial exoantigens could protect 
mice against the development of cerebral malaria after the 
challenge infection given within two weeks after the immunizing 
injections. Furthermore, the immunizing procedure usually did not 
affect the development of parasitemia. 
Chapter 4 
Vascular pathology observed in the brain of mice with cerebral 
malaria is attributed to the deleterious effects of TNF. Treatment 
of infected mice with TNF produced pathology similar to that found 
in cerebral malaria, except that other internal organs were 
affected too. Repeated injections with sublethal amounts of TNF 
could protect mice against cerebral malaria. As for TNF, infected 
mice were also more sensitive to injection with LPS. Mortality 
could not be prevented, however by repeated injections of sublethal 
amounts of LPS though cerebral hemorrhages were not observed 
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during infection. Dexamethasone treatment could not abolish the 
increased sensitivity to TNF. 
Elimination of monocytes/macrophages by treatment with lip-
CI2MDP prevented the development of cerebral malaria when started 
before day 5 of the infection but did not affect the increased 
sensitivity for LPS. 
Chapter 5 
A single injection of mice with IFN-γ, a cytokine produced by 
activated T-cells, induced a transient hypothermia, whereas 
repeated injections resulted in a delay of patency and a decrease of 
parasitemia. Continuous infusion of this cytokine again delayed 
patency and inhibited parasitemia but additionally protected 
against the development of cerebral malaria. Continuous infusion of 
IFN-γ in nude mice also reduced parasitemia but nude mice do not 
normally develop cerebral malaria. Continuous infusion of higher 
doses (104 Units/24 hours) appeared to be lethally toxic in normal 
as well as in nude mice with histopathological changes that were 
also observed in cerebral malaria. 
Treatment of mice with antibodies against IFN-γ resulted in an 
enhancement of parasitemia but did not protect against cerebral 
malaria in this model, although it does to some extend in a model 
used by others in which another parasite and mouse strain were 
used. 
Chapter 6 
Treatment with IL-1 early during infection protected against 
cerebral malaria. Thus, IL-1 treatment before or early during 
infection protects against bacterial, fungal and a parasitic 
infection in mice. Injection of infected mice with IL-1 resulted in a 
decrease of parasitemia in a dose dependent way. This effect of IL-
1 on parasitemia is not observed in nude mice and is probably 
mediated at least in part by the induction of IFN-γ since in normal 
mice simultaneous treatment with antibodies against IFN-γ 
significantly reduced the effect of IL-1. 
The protective effect of IL-1 on cerebral malaria is probably not a 
result from interference with TNF sensitivity because IL-1 treated 
mice remained as sensitive to TNF injection as untreated mice. The 
adjuvants effect of IL-1, however, might explain the protective 
property against cerebral malaria, but so might induction of IFN-γ 
by IL-1. 
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Chapter 7 
Apart from protection against several infections, IL-1 has also 
been incriminated as a deleterious factor during infection. The 
availability of a human IL-1 receptor antagonist (IL-1 га) allowed to 
further investigate the role of IL-1 in infection. 
In malaria infection in mice the IL-lra protected against cerebral 
pathology and additionally suppressed parasitemia although to a 
lesser extend than IL-1. Human IL-1 ra only binds to murine IL-IRti 
which is found on T-cells, endothelial cells and human monocytes 
and not to IL-1 Rti ι which is found on B-cells, neutrophils and 
murine macrophages. This further argues for immunopathological T-
cell dependent reactions in the pathogenesis of cerebral malaria. 
Interestingly, the effect of IL-1 on parasitemia could be reversed 
in part by the IL-lra treatment (to the extend of mice treated with 
IL-lra alone). 
Chapter 8 
In the general discussion final considerations are presented in 
relation to a scheme displaying the possible interrelation between 
several cell types and cytokines as well as their possible role in 
the development of murine cerebral malaria. 
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SAMENVATTING 
Hoofdstuk 1 
De inleiding beschrijft de omvang van het malaria probleem in het 
algemeen en belicht in het bijzonder de hersen malaria. De 
verschillende theoriën omtrent de Pathogenese van humane hersen 
malaria worden beschreven. Daarnaast wordt het dierexperimentele 
model Plasmodium berghenmuis nader beschreven. Tot slot wordt 
het doel van het hier beschreven onderzoek vermeld. 
Hoofdstuk 2 
In het dit hoofdstuk worden immunologische eigenschappen van het 
proefdiermodel beschreven. Hersen malaria ontwikkelde zich in de 
tweede week van de infectie en werd gekarakteriseerd door een 
snelle daling van de lichaamstemperatuur (beneden 30°C) en 
bloedingen in de hersenen gevold door sterfte binnen de tweede 
week van de infectie. Verwijdering of bestraling van de milt, 
behandeling met dexamethasone, anti-T-cell serum of serum van 
malaria-immune muizen kon de ontwikkeling van hersen malaria 
voorkomen. 
Hoofdstuk 3 
Omdat bij de ontwikkeling van hersen malaria immunologische 
reactiviteit een rol bleek te spelen zou het mogelijk moeten zijn 
om tegen deze complicatie te immunizeren. Dit bleek op een aantal 
manieren te verwezenlijken. Naast infectie met een verhoogd aantal 
parasieten bleek ook dat injectie van grote hoeveelheden gedode 
parasieten of parasitaire exoantigenen of een twee dagen durende 
immunizerende infectie gegeven binnen twee weken voor de 
challenge bescherming tegen hersen malaria opleverde. Deze 
behandelingen beïnvloedden in het algemeen niet de ontwikkeling 
van de parasitemie. 
Hoofdstuk 4 
De pathologische veranderingen in het vaatsysteem van de hersenen 
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bij muizen met hersen malaria is toegeschreven aan de effecten van 
tumor necrosis factor (TNF). Injectie van TNF in geïnfecteerde 
muizen veroorzaakte dezelfde pathologie als gevonden bij hersen 
malaria. Deze pathologie bleef echter niet beperkt tot de hersenen 
maar trad ook op in andere inwendige organen. Herhaalde injecties 
van sub-lethale hoeveelheden TNF beschermde muizen tegen hersen 
malaria. Geïnfecteerde muizen waren ook gevoeliger voor lipo-
polysaccharide (LPS) maar in tegenstelling tot TNF kon vroege 
sterfte niet worden voorkomen door herhaalde injecties met sub-
lethale hoeveelheden LPS. Opvallend was dat na sterfte in de 
hersenen van deze dieren geen bloedingen werden aangetroffen. De 
verhoogde gevoeligheid voor exogeen TNF kon niet beïnvloed worden 
door remming van de TNF productie door dexamethasone. Eliminatie 
van monocyten/macrophagen door middel van liposomaal dichloro-
methylene-diphosphonaat (lip-CI2MDP) voorkwam hersen malaria 
alleen indien uitgevoerd binnen vijf dagen na infectie maar beïn-
vloedde niet de verhoogde gevoeligheid voor LPS. 
Hoofdstuk 5 
Een enkele injectie van interferon-y (IFN-γ) in geïnfecteerde muizen 
resulteerde in een tijdelijke daling van de lichaamstemperatuur 
terwijl herhaaldelijke injecties het optreden van hersen malaria en 
de ontwikkeling van de parasitemie vertraagde. Continue infusie van 
IFN-γ bleek hersen malaria te voorkomen. In T-cell deficiente 
muizen (nudes) die van nature geen hersen malaria ontwikkelen 
bleek IFN-γ ook een remmend effect op de parasitemie te hebben. 
Hogere doses IFN-γ bleken toxisch in normale zowel als nude 
muizen. Na sterfte vertoonden de hersenen van deze dieren een 
histopathologisch beeld dat ook aangetroffen werd bij hersen 
malaria. 
Behandeling van geïnfecteerde muizen met antilichamen gericht 
tegen IFN-γ verhoogde de parasitemie maar beschermde niet tegen 
hersen malaria ofschoon dit wel gedeeltelijk het geval was in een 
hersen malaria model dat door anderen gebruikt wordt. 
Hoofdstuk 6 
Het cytokine interleukine-1 (IL-1) bleek bij malaria infectie in 
muizen bescherming op te leveren tegen hersen malaria. Bovendien 
kon de ontwikkeling van de parasitemie geremd worden door 
herhaaldelijke injecties van IL-1. Dit laatste effect kon alleen 
vastgesteld worden bij normale muizen maar niet bij nude muizen. 
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Waarschijnlijk werd het remmend effect van IL-1 op de para-
sitemie gemedieerd door IFN-γ aangezien simultane behandeling van 
muizen met IL-1 en anti-IFN-γ antilichamen het remmend effect van 
IL-1 reduceerde. 
Muizen beschermd tegen hersen malaria door middel van IL-1 waren 
niet ongevoeliger voor injectie van TNF. Mogelijk dat het adjuvants 
effect van IL-1 of de inductie van IFN-γ door IL-1 de beschermende 
werking tegen hersen malaria kan verklaren. 
Hoofdstuk 7 
Naast beschermende effecten van IL-1 in diverse infecties zijn er 
ook nadelige effecten van IL-1 beschreven. Het belang van endogeen 
geproduceerd IL-1 tijdens de infectie kon verder onderzocht worden 
door de beschikbaarheid van een humane IL-1 receptor antagonist 
(IL-1 ra). 
Tijdens malaria bleek endogeen geproduceerd IL-1 van nadelige 
invloed te zijn op de ontwikkeling van hersen pathologie aangezien 
behandeling van muizen met IL-1 ra hersen malaria kon voorkomen. 
Bovendien remde behandeling met IL-1 ra ook de parasitemie 
ofschoon niet zo sterk als IL-1 zelf dit deed. 
IL-1 ra bindt alleen aan de type ι IL-1 receptor bij muizen. Dit type 
komt voor op T-cellen, endotheelcellen en humane monocyten. De IL-
Ira bindt niet aan de type n IL-1 receptor die gevonden wordt op 
B-cellen, neutrophielen en muizen macrophagen. Deze gegevens 
wijzen nogmaals op de betrokkenheid van T-cell afhankelijke 
immunologische reactiviteiten bij de Pathogenese van hersen 
malaria. 
Het effect van IL-1 op de parasitemie kon slechts gedeeltelijk 
worden opgeheven door behandeling met IL-1 ra. Dit zou verklaarbaar 
zijn door de aanname dat zowel cellen met type ι IL-1 receptor als 
wel cellen met type n IL-1 receptor betrokken zijn bij de door IL-1 
geïnduceerde antiparasitaire effecten 
Hoofdstuk 8 
In de algemene discussie wordt een schema gepresenteerd aan de 
hand waarvan de interacties tussen celtypen en cytokinen die een 
rol spelen bij de Pathogenese van hersen malaria worden be-
schreven. 
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